


**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/86, 7/01</b>		(11) International Publication Number: <b>WO 98/56937</b>
<b>A2</b>		(43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: <b>PCT/US98/12158</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 9 June 1998 (09.06.98)		
(30) Priority Data: 60/049,072 9 June 1997 (09.06.97) US 60/072,222 22 January 1998 (22.01.98) US		
(71) Applicant (for all designated States except US): GENVEC, INC. [US/US]; 12111 Parklawn Drive, Rockville, MD 20852 (US).		
(72) Inventors; and (75) Inventors/Applicants (for US only): McVEY, Duncan, L. [US/US]; 6016 Muncaster Mill Road, Derwood, MD 20855 (US). BROUGH, Douglas, E. [US/US]; 3900 Shallowbrook Lane, Olney, MD 20832 (US). ZUBER, Mohammed [US/US]; 4993 Robin Court, Frederick, MD 21703 (US). KOVESDI, Imre [CA/US]; 7713 Warbler Lane, Rockville, MD 20855 (US).		
(74) Agents: KILYK, John, Jr. et al.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US).		

**Published***Without international search report and to be republished upon receipt of that report.***(54) Title: CHIMERIC VECTORS COMPRISING A PHAGE PACKAGING SITE AND A PORTION DERIVED FROM A GENOME OF A EUKARYOTIC VIRUS****(57) Abstract**

The present invention provides an improved method of making eukaryotic gene transfer vectors comprising homologous recombining lambdoid vectors with a second DNA in a bacterium to generate novel recombinant eukaryotic viral gene transfer vectors as well as a novel lambdoid vector used in the inventive method and an inventive system comprising the novel lambdoid vector.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CHIMERIC VECTORS COMPRISING A PHAGE PACKAGING SITE AND A PORTION  
OF A EUKARYOTIC VIRUS DERIVED FROM A GENOME

TECHNICAL FIELD OF THE INVENTION

The present invention pertains to vectors  
5 constructed in a prokaryotic cell for use in gene  
transfer to eukaryotic cells, vectors useful for making  
eukaryotic gene transfer vectors, and methods of making  
the same.

10 BACKGROUND OF THE INVENTION

Gene transfer to eukaryotic cells has both *in vivo*  
and *in vitro* uses. As is well known, *in vivo* gene  
transfer to eukaryotic cells can be used to immunize a  
host, for therapeutic gene transfer to a host, and to  
15 study the biology of transferred genes *in vivo*. *In vitro*  
gene transfer to eukaryotic cells can be used to study  
simple and complex biological phenomena such as protein  
function, protein half-life, and gene-protein  
interactions. One preferred method for transferring  
20 genes to eukaryotic cells has been through the use of  
recombinant eukaryotic viruses. Although researchers and  
clinicians have enjoyed the many advantages of  
recombinant eukaryotic viruses for gene transfer to  
eukaryotic cells, the difficulty of constructing these  
25 viruses has impeded the rate at which new and useful gene  
transfer experiments and protocols have been developed.

Because of their large size, many recombinant  
eukaryotic viruses are produced via homologous  
recombination. Conventionally, homologous recombination  
30 used to generate large viral vectors has taken place in a  
host eukaryotic cell permissive for the growth of the  
recombinant virus (see, e.g., Berkner, BioTechniques, 6,  
616-628 (1988)). Homologous recombination in eukaryotic  
cells, however, has at least two major drawbacks. The  
35 process is time consuming, and many preferred recombinant  
eukaryotic viral constructions are at a selective  
disadvantage relative to the predecessor eukaryotic

viruses from which they are obtained. Therefore, if a skilled artisan attempts to create a new recombinant virus through the lengthy process of homologous recombination in a eukaryotic cell and fails to create  
5 the desired virus, that artisan is often unable to readily distinguish between the need to modify the construction technique and the possibility that the desired virus vector is not viable in the host cell. Accordingly, there is a need for new methods of  
10 generating eukaryotic gene transfer vectors.

Previous improvements in the generation of gene transfer vectors have included the use of yeast-based systems (Ketner et al., Proc. Nat'l. Acad. Sci. (USA), 91, 6186-6190 (1994)), plasmid-based systems (Chartier et  
15 al., J. Virology, 70, 4805-4810 (1996); Crouzet et al., WO 96/25506), and cosmid-based systems (Miyake et al., Proc. Nat'l. Acad. Sci. (USA), 93, 1320-1324 (1996)). While these systems can expedite the production of new recombinant eukaryotic viruses, additional flexibility  
20 and selection pressures are desired. The present invention provides a rapid and flexible method for producing new vectors, which can be used in gene transfer to eukaryotic cells *in vitro* and *in vivo*. The present invention also provides vectors modified for use in  
25 eukaryotic gene transfer, as well as methods and systems for using the same. These and other advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.

30

#### SUMMARY OF THE INVENTION

The present invention provides a DNA vector comprising a portion of a eukaryotic viral genome comprising an ITR, a regulatable negative selection gene  
35 (NSG) or a stringently regulated growth discrimination gene (SRG), and a phage packaging site. The present inventive vector preferably comprises a full eukaryotic

(e.g., adenoviral) amplicon. Moreover the regulatable negative selection gene or growth discrimination gene is preferably embedded within the portion of the eukaryotic viral genome of the present inventive vector such that a double recombination event with a second DNA vector removes the regulatable negative selection gene or growth discrimination gene at the same time that a DNA of interest is transferred into the present inventive vector. In another embodiment of the present inventive vector a positive selection gene is proximal to the NSG, which forms a dual selection cassette (DSC). The combination of negative and positive selection genes forms a dual selection cassette (DSC) that provides the skilled artisan with exquisite control of the homologous recombination system. The SRG can serve either a negative or positive selective function, or both. Accordingly, it is useful to have an SRG proximal to either a PSG or an NSG. SRGs that are adjacent or proximal to another selective gene are termed dual discrimination cassettes. Of course, the present inventive vector can also comprise other genetic elements, such as an independent positive selection gene that is not positionally associated with the NSG, DSC, or SRG and a bacterial origin of replication.

25       The present inventive vector optionally comprises additional advantageous elements. For example, the present inventive vector optionally comprises a deficient or conditionally deficient lambdoid origin of replication, which enhances the effectiveness of double homologous recombination. The present inventive vector is preferably configured such that the phage packaging site is proximal to an ITR of a eukaryotic viral amplicon, which allows for direct generation of an amplicon when the present inventive vector is

35       encapsidated and transduced or infected into a suitable eukaryotic cell.



The present invention also provides for a library comprising or consisting of a multiplicity of the present inventive vector comprising a multiplicity of genetic elements that may be the same or different.

5       The present invention also provides a system for the generation of recombinant DNA vectors. Any embodiment of the present inventive vector can constitute a portion of the present inventive system. The present inventive system comprises at least a second DNA that comprises two  
10 DNA segments each of which have sufficient homology to the inventive vector to mediate homologous recombination and which flank or surround a DNA that is desirable to incorporate into the present inventive vector or into a portion of the eukaryotic viral DNA or amplicon that  
15 forms a portion of the present inventive vector. Certain embodiments of the present inventive system comprise a third DNA that can complement *in trans* a deficiency in a lambdoid origin of replication and, optionally, a fourth DNA that expresses a source of phage capsids that  
20 encapsidate intermediate or product vectors comprising the phage origin of replication. Either or both of the third and fourth DNAs of the inventive system can be optionally incorporated into the genome of a bacterial cell.

25       The present invention also provides a method of making and packaging a DNA vector. The inventive method comprises transfecting a bacterial cell with two DNA vectors that undergo homologous recombination to form a desired DNA vector. One vector comprises a phage  
30 packaging site, and an NSG, DSC, or SRG that is flanked by two DNA segments that mediate a double homologous recombination event with the second vector employed in the system. The double homologous recombination event places a DNA into the first vector and simultaneously  
35 removes the NSG, DSC, or SRG, and introduces a DNA from the second vector into the first vector. The method also includes the use of *in vivo* conditions that encapsidate

the double homologously recombined product that contains a phage packaging site into a phage capsid. The present inventive method can also comprise infecting the encapsidated product vector into a population of cells under conditions such that the negative selection gene is active prior to harvesting the product vector from a lysate of the second cell, which serves to eliminate cells containing undesired DNA constructs from the population of cells from which the product vector is isolated.

The present inventive method optionally employs a first vector comprising a deficient or conditionally deficient lambdoid origin of replication. In this embodiment of the present invention, the deficiencies in the lambdoid origin of replication are complemented in trans during the period of time in which the homologous recombination event occurs, which enhances the efficiency of the process for several reasons.

The present invention also provides an improved method of gene transfer to eukaryotic cells. The improved method comprises using lambdid vectors (defined below) to generate novel recombinant vectors including recombinant eukaryotic viral vectors, that are capable of transferring genes to eukaryotic cells. Lambdid vectors, or portions thereof, also can be transduced into eukaryotic cells without the aid of (eukaryotic viral or phage) coat proteins. Lambdid vectors transduced into eukaryotic cells can generate new recombinant eukaryotic viral vectors, direct heterologous gene expression, or be used for other purposes. Additionally, lambdid vectors can be encapsidated into lambdoid capsids comprising chimeric lambdoid coat proteins capable of binding to eukaryotic cells. These lambdid vectors encapsidated into recombinant capsids can be used to directly transduce eukaryotic cells.

These and other features of the present invention are more fully described below.



BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the lambdid vector  $LOI^QVXB(Spe)$ .

Figure 2 depicts the lambdid vector  $LOI^QVXB(SpeCC)$ .

5 Figure 3 depicts the lambdid vector  $LI^QVXB(Spe)$ .

Figure 4 depicts the lambdid vector  $LGV_{11}VXB$ .

Figure 5 depicts the structure of several DNA vectors useful in the context of the present invention, particularly L-sel. Figure 5 also depicts the interrelationship of the DNA constructs when used in one embodiment of the present inventive method.

Figure 6 depicts lambdid vector  $LOI^QVX-Ad_{Gv}VEGF_{121}$ . 10. This vector can be encapsidated in a gene D-modified lambda capsid to produce an encapsidated DNA vector comprising an adenovirus carrying an expression cassette for  $VEGF_{121}$ . The encapsidated vector can be contacted with a eukaryotic cell having a receptor or ligand specific for the chimeric gene D coat protein. The eukaryotic cell will then take up the encapsidated vector. If the eukaryotic cell is permissive for the replication of the adenoviral vector that is a part of the encapsidated lambdid vector, then a stock of adenoviral vectors can be obtained from the cell. Irrespective of the ability of the DNA vector to replicate in the eukaryotic cell, the  $VEGF_{121}$  passenger gene can still be expressed in the cell.

Figure 7 depicts one embodiment of Vector 7, a lambdid vector of the present invention.

Figure 8 depicts one embodiment of Vector 8. Vector 8 can be used in combination with Vector 7 (see Example 8 below).

Figure 9 depicts an embodiment of Vector 9. Vector 9 is one of the desirable products that can be obtained by homologous recombination between Vector 7 and Vector 8.

Figure 10 depicts some of the by-products of homologous recombination between Vector 7 and Vector 8.

Example 8 illustrates a useful method for making and isolating Vector 9 from Vectors 7 and 8 and the vectors depicted in Figure 10.

Figure 11 depicts a preferred embodiment of the present invention. In Figure 11 a first vector and a second vector undergo double homologous recombination to form a product vector. The product vector is isolated from other vector forms by the application of positive and negative selective pressure and by the use of phage encapsidation and infection.

Figure 12 depicts a preferred embodiment of the present invention. The embodiment of the present invention depicted in Figure 12 is nearly identical to the embodiment depicted in Figure 11, except that in Figure 12 one ITR of a eukaryotic viral genome is resident in the first vector and another ITR of a eukaryotic genome is resident in a second vector and the double homologous recombination transfers the ITR of the second vector to the product vector to form a eukaryotic viral amplicon.

Figure 13 depicts p15E1(Z). p15E1(Z) is a second vector of the present invention. The plasmid comprises the p15 ori and a kanamycin resistance gene obtained from pACYC177. The bla gene from pACYC177 was replaced with Ad5 sequences 1 to 5,788. Adenoviral sequences 356 to 3327 were replaced with an expression cassette comprising the CMV promoter operably linked to the Lac Z gene and an SV40 polyadenylation signal.

Figure 14 depicts pAdE1(BN)E310BR and is a pSelect of the present invention. The Sty I site of pBR322 was changed to Pac I. The Lac I<sup>q</sup> expression cassette and a cos site were inserted into the Pac I site. Adjacent to the cos site are adenoviral sequences 1 to 35,935 in which sequences 356 to 4122 are replaced with a DSC and sequences 28,592 to 30,470 (Xba I to Xba I) are deleted. The EM-7 promoter of the DSC is oriented toward the left

ITR. The right ITR is next to the Pac I site that is closest to the tetracycline resistance gene.

Figure 15 depicts pAdE1(Z)E3(10)BR, which is a pDesired vector of the present invention.

5 pAdE1(Z)E3(10)BR is isogenic with pAdE1(BN)E310BR except that the Lac Z expression cassette of p15E1(Z) and adenoviral sequences 3328 to 4122 have replaced the DSC.

Figure 16 depicts pAdE1(Z)E3/4(B)IQCos, which is a first vector (or pSelect) of the present invention.  
10 comprising an SRG. This vector comprises a serotype 5 adenoviral genome modified by (i) replacing coordinates 356 to 2,787 with an expression cassette comprising the CMV promoter operably linked to the Lac Z gene and an SV40 polyadenylation sequence, and (ii) replacing  
15 coordinates 27,084 to 35,564 with an SRG.

#### DETAILED DESCRIPTION OF THE INVENTION

##### Definitions

Certain terms are used with particular meaning, or  
20 are defined for the first time, in this description of the present invention. For the purposes of the present invention, the following terms are defined by their art-accepted definitions, when such exist, except that when those definitions conflict or partially conflict with the  
25 definitions set forth below. In the event of a conflict in definition, the meaning of the terms are first defined by the definitions set forth below.

**Transfected** means any suitable method of transferring a DNA from the outside of a cell to the  
30 inside of a cell so that the cell remains biologically viable. Suitable methods of transfection include, but are not limited to, infection, chemical transformation, electroporation, microparticle bombardment, and other techniques known in the art.

35 The term lambdoid is an art-accepted adjective that denotes that the noun it modifies is of a phage having a high degree of similarity to bacteriophage Lambda. In

contrast, the term **lambdid** vector refers to certain embodiments of the present inventive DNA vector. Lambdid vectors are so-named because they comprise an operon that comprises a lambdoid origin of replication. One  
5 preferred embodiment of a lambdid vector is described in detail in Example 8 below.

An **amplicon** is a vector capable of replicating and being packaged when any deficient essential gene functions are provided *in trans*. A eukaryotic viral  
10 amplicon includes at least a portion of each terminal repeat required to support the replication of the viral DNA and the DNA required to encapsidate the genome into a viral capsid. Eukaryotic viral amplicons preferably comprise at least about 90% of the full ITR sequence.

15 In certain embodiments of the present invention, bacteria are transferred from a liquid culture medium to solid culture medium, ("plated") in such a manner that individual bacteria grow to form clonal colonies of a single bacterium from the liquid culture. The skilled  
20 artisan will appreciate that colonies appear at variable rates when a mixture of bacteria are plated and some bacteria have a growth advantage relative to the other bacteria in the culture. Those bacteria that grow rapidly and form visible colonies of at least about 2 mm  
25 in diameter before other colonies appear are called **primary colonies**. Colonies that are not clearly visible to the naked eye for at least about twelve hours, and preferably at least about 30 hours, after the clear appearance of primary colonies are called **secondary**  
30 **colonies**.

A **stringent promoter** is one that is not recognized by an *E. coli* or other bacterial host RNA polymerase, but rather by a polymerase that recognizes only a small family of highly homologous DNA sequences. Stringent  
35 promoters are typically phage promoters, e.g., the T7 promoter, the T3 promoter, and the Sp6 promoter.

The abbreviations **NSG**, **DSC**, **SRG**, **PSG**, and **DDC** are used herein to denote negative selection gene, dual selection cassette, stringently regulated gene, positive selection gene, and dual discrimination cassette. These terms are defined below.

The term **anti-selective gene** comprises NSGs and SRGs which substantially inhibit the growth of cells comprising the same, when the gene is activated. DSCs comprise NSGs and, therefore, also comprise anti-selective genes.

The term **comprising** is used in the description of the invention and in the claims to mean "including, but not necessarily limited to".

The term **embedded** when applied to DNA vectors is used to refer to sequences which are inserted into or in place of the sequence in which they are embedded. Embedded sequences can be adjacent to spacer sequences. Spacer sequences that form a portion of an embedded sequence are preferably less than about 250 base pairs in length and preferably do not encode for a biological function. The term **adjacent** when applied to DNA vectors refers to sequences that are separated by less than about 30 base pairs. Adjacent sequences are preferably separated by less than about 12 base pairs. The term proximal refers

#### The Invention

Double homologous recombination has been conventionally used to make large DNA vectors. The present invention provides, *inter alia*, a DNA vector, and a system for making a recombinant DNA vector, that enables the present inventive method, which comprises using double homologous recombination, to take place in bacteria with an unprecedented ease and with an ability to affirmatively control the reaction that produces the desired vector.

The present invention provides a method of making and packaging a recombinant DNA vector. The inventive method comprises transfecting a bacterial cell with two DNA vectors that undergo homologous recombination to form  
5 a desired DNA vector. One vector (i.e., the acceptor or first vector) comprises a phage packaging site, and an anti-selective gene (an NSG, SRG, DSC, or DDC) that is flanked by two DNA segments that mediate a double homologous recombination event with the second vector  
10 employed in the system. The double homologous recombination event produces a desired product vector by introducing a DNA from the second vector into the first vector and simultaneously transferring the anti-selective gene from the first vector to the second vector. The  
15 product vector advantageously comprises a phage packaging site. In that regard, the method preferably includes the use of *in vivo* conditions that encapsidate the product vector made by the double homologous recombination into a phage capsid. The present inventive method preferably  
20 continues by infecting the encapsidated product vector into a population of cells (which population is different from the cell in which the homologous recombination occurs) under conditions such that the anti-selective gene is active prior to harvesting the product vector  
25 from a lysate of the second cell, which serves to eliminate cells containing undesired DNA constructs from the population of cells from which the product vector is isolated.

The present inventive method optionally employs a  
30 first vector comprising a lambdoid origin of replication. The lambdoid origin of replication is preferably a deficient or conditionally deficient lambdoid origin of replication. However, the advantage of the lambdoid origin of replication is mainly derived from its  
35 operation during the double homologous recombination of the present inventive method. This replication enhances the efficiency of the process by providing an elevated

rate of homologous recombination and by providing greater amounts of DNA. The deficiencies in the lambdoid origin of replication are complemented *in trans* during the period of time in which the homologous recombination event occurs. Various deficient lambdoid origins of replication are described herein below as well as methods of activating these origins. Moreover, as discussed below it is advantageous to prevent lambdoid replication during the remainder of the present inventive method. Accordingly, the employment of a deficient or conditionally deficient lambdoid origin of replication constitutes one preferred embodiment of the present invention.

Various embodiments and improvements of the present inventive method exist and are dependent, in part, upon the design of the present inventive vector, either alone or in combination with the design of the second inventive vector. Other embodiments of the present inventive method are dependent upon the inclusion of a helper phage or lysogen, and upon the characteristics of the cell or population of cells used to carry out the present inventive method.

The present inventive DNA vector (i.e., the first or acceptor vector) comprises (i) a portion of a eukaryotic viral genome comprising an ITR, (ii) a regulatable negative selection gene (NSG) or a stringently regulated growth discrimination gene (SRG), and (iii) a phage packaging site. The present inventive vector preferably also comprises at least one origin of replication that is operable in a bacterial cell. This origin may be any suitable origin but is preferably a low copy number, non-phage origin to enhance the stability of the vector. A preferred bacterial origin is the pBR322 origin. Other suitable origins include, but are not limited to, p15A, pSC101, and RK2.

The portion of the eukaryotic viral genome of the first vector can also contain a second ITR, which creates

an amplicon lacking a packaging site. Instead of, or in addition to a second ITR, the portion of the eukaryotic viral genome can also comprise a eukaryotic viral packaging site. Thus, the first vector optionally  
5 contains a eukaryotic viral amplicon.

The present inventive vector is preferably circular, because such vectors are generally easier to propagate and maintain in bacteria.

As stated above, the present inventive vector  
10 comprises an anti-selective gene, which can be either a regulatable NSG or an SRG. In certain embodiments of the present invention, the anti-selective gene is embedded within the portion of a eukaryotic vector of the first vector. This is particularly useful, when a terminal  
15 portion of the eukaryotic viral genome is not to be replaced by the double homologous recombination event so that when the double homologous recombination event takes place the anti-selective gene is removed from the product vector. However, the anti-selective gene does not need  
20 to be embedded within the eukaryotic viral genome in those instances when a region outside the eukaryotic viral genome of the first vector participates in the homologous recombination. In either embodiment, the present inventive vector is designed such that the double  
25 recombination event with a second DNA vector removes the anti-selective gene at the same time that a DNA of interest is transferred into the present inventive vector to form the product vector.

In another embodiment of the present inventive  
30 vector a positive selection gene (PSG) is placed proximally to or adjacent to the anti-selective gene. The combination of negative and positive selection genes forms a dual selection cassette (DSC) that provides the skilled artisan with exquisite control of the homologous  
35 recombination system. For example, in the process of forming the present inventive vector, the positive selection gene can be used to select for colonies of



bacteria that harbor the PSG and therefore the DSC comprising the NSG. Additionally, the PSG of the DSC can be used to generate selective pressure against vector forms that spuriously recombine or otherwise change to eliminate the NSG. In each of these embodiments, an SRG  
5 can be substituted for a NSG of the DSC.

Of course, the present inventive vector can also comprise other genetic elements, such as an independent positive selection gene that is not positionally  
10 associated with the NSG, DSC, or SRG and a bacterial origin of replication. An independent positive selection gene is not removed from the present inventive vector by the double homologous recombination event. Preferably, the independent PSG is not embedded within the portion of  
15 the eukaryotic viral genome that resides in the present inventive vector. The independent PSG is useful for, *inter alia*, providing positive selection pressure for bacteria harboring a desired product vector obtained from homologous recombination between a vector comprising an  
20 NSG or DSC and another vector.

The PSG of the DSC (when applicable) and the independent PSG can be any suitable gene. A PSG comprises a DNA encoding an RNA or a protein that provides a selective growth advantage to bacteria  
25 expressing the positive selection gene product under definable conditions. Antibiotic resistance genes and auxotrophy complementing genes are examples of positive selection genes suitable for use in the present invention. Suitable PSGs that confer antibiotic  
30 resistance to a host cell include, but are not limited to, kanamycin, ampicillin, tetracycline, and zeocin resistance genes. Tetracycline and zeocin genes function better than other PSGs in some embodiments of the present invention and have functioned as well as any other PSG  
35 tested in other embodiments of the present invention. That is, bacterial cells harboring DNA vectors of the present invention are less prone to becoming mucoidal and

are often more susceptible to the NSG, when the genes encoding resistance to tetracycline and/or zeocin are incorporated into the present inventive vector, than when the genes encoding ampicillin or kanamycin resistance are incorporated into the present inventive vector.

5 Therefore, it is often preferable to use tetracycline and zeocin resistance genes for the PSG(s) of the present invention.

The positive selection gene promoter can be any suitable promoter, but it will be appreciated that a constitutive promoter is preferable for many embodiments of the present invention, at least inasmuch as the artisan then need not attend to the function of the positive selection gene promoter. In a DSC, the positive selection gene promoter is preferably positioned and/or oriented so that it does not promote transcription of an RNA encoding the negative selection gene product (i.e., does not promote transcription of a sense-strand RNA of the negative selection gene). This can be accomplished, *inter alia*, by placing the positive and negative gene promoters in a 5' to 5' (or back to back) orientation, such that transcription starts at each promoter and proceeds away from the other, as is depicted in Figure 7.

10  
15  
20

Additionally, the second vector of the present invention can comprise a PSG. The PSG of the second vector is preferably different than the DSC-associated PSG (when present), or the independent PSG, of the present inventive vector.

25

The NSG of the present invention comprises a DNA encoding a negative selection gene product and, operably linked thereto, a negative selection gene promoter, as well as other elements required for the transcription and translation (if appropriate) of a negative selection gene product. The negative selection gene product is any RNA or protein that can confer a strong growth disadvantage to a host cell expressing it or, preferably, that causes

30  
35

the death of a host expressing it under definable conditions.

Suitable negative selection genes include, but are not limited to, NP-1, sacB, ccd genes (e.g., ccdB), a tetracycline gene (tet<sup>R</sup>), par genes (e.g., parD), and Kid. Suitable NSGs also include fusion proteins of these genes (e.g., genes comprising portions of these genes fused to portions of the genes encoding thioredoxin,  $\beta$ -galactosidase, the OmpA signal sequence, luciferase, protein A or any other suitable fusion partner). Suitable NSGs also include active variants of the aforementioned genes, which can comprise deletions, mutations, or other modifications. In short, a suitable NSG provides for the death or substantial decrease in the growth rate of a bacterium expressing the same. A discussion of NSGs can be found in chapter 22 of Escherichia coli and Salmonella, 2<sup>nd</sup> edition, (1996) Niedhardt ed., ASM press, particularly on pages 2317-2318.

By way of further illustration and not limitation, it is noted that the DNA encoding an OmpA FLAG/NP-1 fusion protein is illustrative of an NSG that is useful in the context of the present invention. The OmpA FLAG/NP-1 gene product is a rat defensin fusion protein that lacks its cognate signal sequence and further comprises the OmpA signal sequence and a Flag M1<sup>TM</sup> or Flag M2<sup>TM</sup> antibody (Eastman Kodak). The production of an OmpA FLAG/Np-1 fusion protein in a bacterium renders that bacterium non-viable. While not intending to be bound by any particular theory, one explanation for the negative selection action of OmpA FLAG/Np-1 is that the OmpA signal localizes the NP-1 portion of the protein in, or proximally to, a bacterial membrane such that the NP-1 portion of the protein forms pores in that membrane and destroys the host cell's viability.

The sacB gene is illustrative of another NSG that is useful in the context of the present invention. The sacB

gene-product converts sucrose (when provided in the growth medium) to leaven. Leaven is highly toxic to bacteria. The *sacB* NSG can be regulated by providing or withholding sucrose from a bacterial host that

5 constitutively expresses *sacB*.

The negative selection gene promoter can be strongly regulatable (i.e., inducible, suppressible, or both inducible and suppressible) so as to provide control over the negative selection pressure that the NSG provides.

10 Alternatively, if the NSG promoter is not regulatable, then a suitable means for preventing the function of the negative selection gene must be used. Suitable means for controlling the function of an NSG include, but are not limited to, withholding or providing a substrate that the

15 NSG product converts into a toxin (e.g., sucrose for the *sacB* gene) or providing *in trans* a powerful regulator of the negative selection gene product or promoter (e.g., T7 RNA polymerase).

The Tac promoter (a Trp and Lac hybrid promoter that

20 is well known in the art) is repressible by the *Lac I* protein and inducible by IPTG, and is illustrative of a suitable negative selection gene promoter that is especially useful when the activity of the NSG product is not regulatable (e.g., with OmpA FLAG/NP-1). To achieve

25 a sufficient level of control over the Tac promoter, it is preferable to use this promoter in combination with a bacterial strain that overexpresses the repressor protein (e.g., a *LacI*<sup>0</sup> strain) or to provide the *LacI*<sup>0</sup> gene on a vector in the bacterial cell.

30 The stringent promoter operably linked to an open reading frame comprising a strong signal for the initiation of translation serves a similar function as the NSG of other embodiments of the present invention. When the stringent promoter is activated, e.g., by

35 placing it in a cell that is expressing a stringent polymerase, the stringently regulated gene produces a strong stress on the host cell. As a consequence, plated

colonies of that cell are substantially growth retarded. If a host cell comprising an activated stringently regulated gene is plated from a culture comprising identical or nearly identical cells that do not comprise an active stringently regulated gene, then that host cell will either not form colonies or give rise only to secondary colonies which can easily be segregated from those cells giving rise to primary colonies. This is routine for those skilled in the art. For example, the primary colonies can be re-plated or streaked onto a second solid growth medium so that individual colonies on the second growth medium comprise only cells giving rise to primary colonies. Optionally, additional routine steps can be taken to decrease the probability of secondary colony supporting cells from contaminating cultures of those cells that form primary colonies. This routine process is more fully known as pure-culturing.

Advantageously, an SRG can function both as a selective and anti-selective gene (as a dual-discrimination gene). For example, a gene comprising an EM-7 promoter and encoding zeocin resistance protein or encoding a lacZ-zeocin resistance fusion protein can be incorporated into the present inventive vector. The DNA fragment comprising the EM-7 promoter actually contains two promoters. One promoter is a constitutive promoter recognized by bacterial host cell polymerases. Embedded within the DNA fragment comprising the EM-7 promoter is a T7 promoter, which is recognized only by T7 RNA polymerase. In a cell lacking the T7 RNA polymerase, this SRG provides a strong positive selective pressure in the presence of zeocin or zeocin analogues. Thus, the SRG is a PSG. However, when this SRG is placed in a cell expressing T7 RNA polymerase, the SRG expression causes the cell to grow very slowly or to die. T7 polymerase can be constitutively or inductively expressed from the bacterial genome or a plasmid in the cell, or can be provided by superinfection with a phage. Thus, this SRG

can be used to select for cells comprising the SRG by adding zeocin or a zeocin analogue to the growth medium and can be used to anti-select cells comprising the SRG by ensuring that T7 RNA polymerase is expressed in the  
5 cells. While applicants do not wish to be bound by any particular theory, it is believed that the stringent RNA polymerase has a substantially higher affinity for nucleotides than host RNA polymerases and that when the T7 RNA polymerase directs the expression of the SRG the  
10 host cell's metabolic processes are so depleted that the growth rate of the cell is severely attenuated. This action appears to be much stronger when the RNA transcript of the T7 polymerase directs the translation of a substantial open reading frame (ORF) (at least about  
15 15 amino acids in length, but preferably greater than about 30 or 100 amino acids in length) and when the ORF is preceded by a strong Shine-Dalgarno sequence.

Optionally, the embodiments of the present inventive vector that comprise a dual-discrimination site (such as  
20 the EM-7-lacZ-zeo SRG discussed above) can also comprise a PSG or NSG located adjacent to or proximal to the SRG to form a DNA segment that is analogous to the DSC described above. If a PSG is adjacent to the SRG, then the SRG preferably encodes an anti-selective gene  
25 product, a marker gene product, or other gene product of interest since any positive selective effects of the SRG would be merely redundant. However, if the SRG encodes for a gene product that provides positive selective pressure for a cell expressing it, then the SRG is  
30 optimally placed adjacent to an NSG, which can be used to amplify the negative selective pressure on cells comprising and expressing the DDC.

The present inventive vector and second vector are preferably configured such that the phage packaging site  
35 is proximal to an ITR of a eukaryotic viral amplicon of the product vector. In many embodiments of the present invention this is easily achieved by placing the phage

packaging site proximally to the (first) ITR of the first (present inventive) vector. Such a configuration allows for direct generation of an amplicon when the product vector is encapsidated into a phage capsid and transduced or infected into a suitable eukaryotic cell. This is true because many phage linearize DNA to be packaged and because if an ITR or LTR is suitably proximal to a free terminus of a DNA that comprises a eukaryotic viral amplicon, and that linear DNA is delivered to a eukaryotic cell permissive for the replication of the eukaryotic amplicon, then replication of the eukaryotic viral amplicon can occur. By proximal, it is meant within about 250 base pairs, preferably within about 100 base pairs, and more preferably within about 25 base pairs.) In other words, proximity of an ITR or LTR to a packaging site allows for the replication of the eukaryotic viral DNA/vector in a eukaryotic cell without the need to linearize or cut the DNA with restriction enzymes prior to transfection into the eukaryotic cell.

The present invention also provides an improved method of gene transfer to eukaryotic cells. The improved method comprises using lambdoid vectors (defined below) to generate novel recombinant vectors including recombinant eukaryotic viral vectors, that are capable of transferring genes to eukaryotic cells. Lambdoid vectors, or portions thereof, also can be transduced into eukaryotic cells without the aid of (eukaryotic viral or phage) coat proteins. Lambdoid vectors transduced into eukaryotic cells can generate new recombinant eukaryotic viral vectors, direct heterologous gene expression, or be used for other purposes. Additionally, lambdoid vectors can be encapsidated into lambdoid capsids comprising chimeric lambdoid coat proteins capable of binding to eukaryotic cells. These lambdoid vectors encapsidated into recombinant capsids can be used to directly transduce eukaryotic cells.

An embodiment of the present inventive method comprises transducing a lambdoid vector comprising a negative selection gene and Vector 8 (defined below) or another suitable DNA into bacteria that are susceptible to infection by a lambdoid phage (e.g., lambda), culturing the transduced bacteria under conditions that are selective for the lambdoid vector (or, preferably, selective for the lambdoid vector and Vector 8), and infecting the culture with a helper phage. The vectors homologously recombine, generating a bacterial culture that comprises bacteria carrying a population of vectors, including reactant vectors, desired product-vectors, and undesired product-vectors. Some of these vectors (within the bacteria) are packaged into capsids. The present inventive method facilitates the isolation of those product-vectors which are desired by applying selective mechanisms (e.g., resistance to antibiotics, preferential capsid packaging, etc.). Although the desired product-vectors are likely to be generated at only a very low frequency in each population, means for automatically selecting the desired vectors are incorporated into the present inventive method.

As noted above, the present inventive vector optionally comprises a lambdoid origin of replication, which enhances the effectiveness of double homologous recombination. Also as noted above, the operon comprising a lambdoid origin of replication is preferably conditionally inoperative. Conditional inoperability of the origin of replication provides a number of advantages including, but not limited to, the prevention of "runaway" replication. In one embodiment of the inventive lambdoid vector, a DNA segment can be taken from a lambdoid phage and modified such that at least one essential gene required for the operation of the lambdoid origin of replication is deficient or conditionally deficient. The deficient essential gene function can be of the phage or of the host, but is preferably of the



phage. For example, the operon can contain a gene encoding for an important replicative gene required for the operability of the origin (which is not redundant on the vector). In this case, a deletion can be made in an essential region of the DNA encoding a replicative gene function or a mutation in the DNA encoding the gene function can be made that encodes a frameshift mutation in the amino terminal portion of the gene product. Alternatively, an essential gene function can be conditionally eliminated such that the lambdoid origin of replication becomes conditionally inoperable. The deficient or conditionally deficient gene is preferably one derived from the phage, and most preferably a replicative gene of the phage (e.g., O or P of lambda), so that the deficiency or conditional deficiency does not significantly impair normal bacterial host metabolism, propagation, or function. Additionally, as will be discussed below, the lambdoid origin of replication can be made conditionally inoperable by placing it under the control of a tightly and inducibly regulated promoter.

When it is desirable for the lambdoid origin of the lambdid vector to be operable, the deficiency or conditional deficiency in the essential gene function required for the operability of the origin can be complemented *in trans*, inducibly *in cis* from a separate operon of the lambdid vector, or inducibly *in cis* from within the operon (e.g., by changing the growth conditions such as by shifting incubator temperature from restrictive to permissive). An operon in the context of the present invention is an active or activatable promoter and the DNA sequences encoding the RNA transcribed by the promoter. The transcription of RNA is important because it is required for suitably efficient DNA replication originating at the lambdoid origin of replication. However, the RNA transcribed from an operon does not necessarily encode a protein.

The lambdoid origin of replication can similarly be taken from any other suitable lambdoid phage or be highly homologous to the same. Exemplary lambdoid phage include any of the group having an immunity defined by the  
5 lambdoid phage lambda, 21,  $\phi$ 80,  $\phi$ 81, 82, 424, and 434. Of course, the origin can be taken from any of these prototypical phage themselves. Additionally, the origin of replication may be synthesized by methods that are well known in the art.

10 The lambdoid origin of replication suitable for use in the context of the present invention can be from lambda. The DNA sequence of lambda is publicly available in the Genbank database (accession symbol LAMCG) and elsewhere. The coordinates of suitable DNA fragments of  
15 lambda include (1) 37,951-39,591 with a deletion of 38,041-38,653 (i.e., the  $P_R$  promoter through gene O with Cro-CII deleted), (2) 38,663-39,591 (i.e., all of the O gene and some flanking sequences), (3) 39,004-39,200 (a relatively small conditionally operable origin), and (4)  
20 39,004-39,173. The skilled artisan will be aware of the O protein binding sites (iterons), the A/T rich region and the dyad symmetry sequence downstream of this site (usually comprising an Eco RI site). It will be appreciated that more efficient operation of the present  
25 invention can be obtained by including one or more iterons and the dyad symmetry sequence in the lambdoid origin, although depending on the context of the DNA construct, these sequences can be deleted or altered.

In addition to the wild type origin sequence, a  
30 modified lambda sequence can also be used. For example, coordinates 39,095-39,118 can be deleted, which unconditionally inactivates the origin. When a "G" residue is inserted into the deleted region and the "A" residue at position 39,076 is deleted, the operability of  
35 the origin caused by the first mutation is reversed and an operable, modified lambda origin of replication is obtained. With this modified origin of replication, the

following DNA segments form origins of replication useful in the context of the present invention: (5) 38,663-39,591 (contains all of gene O and some flanking sequences), (6) 39,004-39,200 (a smaller DNA that contains all the binding sites and symmetry sequences of the origin), and (7) coordinates 39,004-39,173 (which is a relatively small origin that retains the ability to respond to O and P).

Other lambdoid origins of replication can be used as well. For example, a DNA comprising coordinates (8) 3,253-5,159 having been deleted of coordinates 3,355-4,148 of the Phi80 (Genbank Accession Symbol BP80ER) sequence is useful in the context of the present invention. This sequence contains the  $P_R$  promoter through the O gene with the sequences comprising the Cro through the CII genes being deleted. Useful smaller fragments of this sequence include coordinates (9) 4,188-5,159 (the O gene and some flanking sequences), (10) 4,567-4,764 (all origin binding sites and some flanking sequences), and (11) 4,567-4,727 (which is a relatively small origin fragment). In addition to the origins described above, the origin can be derived from Phi82. For example, the following sequence (12) is from Phi82 and useful in the context of the present invention.

```

25      SEQ ID NO:1:      tacgcgcat  gcaaatagagt  tgctggaagc  30
      tgtgatgctg  gccggattaa  cacagcacca  gcttctgggc  ttcctggctg  80
      tcatgcgcaa  aacatatggc  tttaataaaa  aactggattg  ggtgagcaac  130
      gagcaacttt  ccgagttgac  cgggatattg  ccgcacaagt  gttctgctgc  180
      aaaaagcgtt  ctggtaaagc  gtgggattct  tattcagagc  gggcggaata  230
30      tcggcattaa  taatgtggtc  agtgaatggt  caacattacc  cgaatcaggt  280
      aagaaaaata  aagtttacct  gaaagaggta  aatttacctg  aatcaggtaa  330
      aaaaagttta  cccaaatcag  gtaaaggcgt  ttaccggaat  caggtaaaca  380
      caaaagacaa  actaacaaaa  gacaatataa  aacctttttc  gtccgagaat  430
      tctggcgaat  cctctgacca  accagaaaac  gatcttc.      465
35

```

Additionally, (13) coordinates 235-467 and (14) 235-432 of this sequence are also useful in the context of the present invention. Of course, the examples of suitable origins of replication given above illustrate the present invention, but are not meant to limit it. Additionally, some of these sequences comprise the  $P_R$

promoter, while others do not comprise a promoter. It will be appreciated that each of these origins require transcription to support DNA replication and that a suitable promoter is to be provided. Further information regarding lambdoid origins of replication can be obtained from Moore et al., "Sequence organization of the origins of DNA replication in lambdoid coliphages", Gene, 14, 91-101 (1981); Grosschedl et al., "DNA sequences and structural homologies of the replication origins of lambdoid bacteriophages", Nature, 277, 621ff, (1979); Moore et al., "Dissection and Comparative Anatomy of the origins of replication of lambdoid phages", Cold Spring Harbor Symp. Quant. Biol., 43 (pt1), 155-163 (1979); Rybchin, "Genetics of bacteriophage  $\phi$ 80 - a review", Gene, 27, 1-11 (1984); and Campbell, "Comparative molecular biology of lambdoid phages", Annu. Rev. Microbiol., 48, 193-222 (1994).

The phage packaging site of the present inventive vector can be from any phage. The lambdoid origin of replication, if included, is preferably obtained from the same phage as the phage packaging site but also can be obtained from a different lambdoid phage or a non-lambdoid phage (e.g., T7). The packaging site can be selected from any phage but is chosen, in part, to accommodate the size of the lambdoid vector. For example, T7 capsids package a smaller genome than lambda capsids. Therefore, if a T7 packaging site is incorporated into a the present inventive vector, then a smaller vector can be efficiently packaged into the relatively smaller capsid of T7. In contrast, if a lambda packaging site is incorporated into the present inventive vector, then the lambdoid vector can be much larger without substantially reducing the efficiency of packaging. The lambda packaging site, cos, is among those phage packaging sites preferred in the context of the present invention.

The packaging site also can be selected to comport with the use of particular phage coat proteins. For

example, chimeric T7 coat proteins having affinity for eukaryotic cells can be made. If it is desired to package the present inventive vector into a capsid comprising such a chimeric T7 coat protein, then it is preferable to use a T7 packaging site in the present  
5 inventive vector. Similarly, incorporation of a chimeric lambda protein dictates that the present inventive vector comprises a lambda packaging site.

A lambdid vector preferably does not comprise all of the structural genes of a lambdoid phage, and can contain no phage structural genes. In some embodiments of the present invention, the only lambdoid sequences contained in the lambdid vector are those of the O gene of Lambda comprising the Lambda origin of replication. In still  
10 other embodiments, the only lambdoid sequences of the lambdid vector are the lambdoid origin of replication and a lambdoid phage packaging site. Consequently, a lambdid vector usually has the capacity to carry a substantial amount of non-lambdoid DNA and still be efficiently  
15 encapsidated into a phage capsid.

In contrast to other embodiments of the present inventive vector, lambdid vectors need not have, and can be used without, a constitutively functional origin of replication. However, a constitutively functional origin  
20 of replication allows for the stable maintenance of the lambdid vector in a bacterial cell. Therefore, a source of the deficient or conditionally deficient gene function necessary for the operability of the lambdoid origin of replication can be constitutively supplied in a bacterium  
25 comprising the lambdid vector. Under such circumstances, the lambdid vector can be maintained in the bacterium by the lambdid origin of replication. However, lambdoid origins of replication can be unstable. Moreover, the result of continuous operation of the lambdoid origin  
30 could mediate runaway replication. These effects can be deleterious. Therefore, a lambdoid vector can advantageously comprise a second origin of replication

which functions independently of the lambdoid origin of replication. Preferably, the second origin of replication is of a bacterial origin.

5 A library comprising a multiplicity of the present inventive vector also can be obtained. The inventive vector library can be constructed from a population of DNA sequences comprising a multiplicity of eukaryotic genetic elements or amplicons. Alternatively, the inventive lambdid vector can be homologously recombined  
10 with a population of DNA sequences with each DNA of the population comprising a DNA segment having high homology to the lambdid vector, preferably having high homology to the eukaryotic amplicon. It will be appreciated that these libraries have a multiplicity of utilities  
15 including the study of functional genomics (e.g., identifying the functions and identities of genomic and complementary DNA sequences), viral vector design, structure-function studies of individual genes or gene products, and more.

20 Any suitable promoter can be linked to the DNA segment comprising the lambdoid origin of replication. Examples of suitable promoters include the trp operon promoter, the tRNA<sup>tyr</sup> promoter, the Tet promoter, the lac operon promoter, the recA promoter, the lexA promoter,  
25 the T7A3 promoter, and synthetic promoters (e.g., a TTGACA sequence at the -35 region and a TATAAT sequence at the -10 region). These promoters can be used with or without the regulatory regions that naturally accompany them.

30 One preferred embodiment of the present invention comprises an operon containing a lambdoid origin of replication that is driven by the P<sub>R</sub> promoter of lambda (i.e., about sequence coordinates 38,041 to 40,284 of Genbank Accession Symbol LAMCG). The P<sub>R</sub> operon drives the  
35 transcription of the operon comprising the origin of replication in wild-type lambda and can be incorporated into a lambdid in its entirety, but is preferably

rendered deficient or conditionally deficient in at least one gene function required for operability of the origin of replication. Some allowable and preferable modifications of the  $P_R$  operon are discussed directly below.

The P protein encoded by the P gene of the  $P_R$  operon is normally required in the assembly of the phage replication complex at the lambda origin. However, when expressed at high levels, P can interfere with host genome and plasmid replication. Additionally, P encodes a gene function required for the operability of the lambdoid origin of replication. Therefore, a recombinant lambdoid phage vector comprising the lambda  $P_R$  operon is preferably deficient or conditionally deficient in at least the gene encoding P.

Other gene functions that can be deficient in a lambdoid vector comprising the lambdoid operon include the functions of Cro, CII, tR, O, and Oop transcription.

Cro autoregulates the  $P_R$  promoter. This autoregulation of  $P_R$  can be disadvantageous. If the  $P_R$  promoter is used to drive transcription of the lambdoid operon comprising the lambdoid origin of replication or if a lambdoid helper phage or lysogen (see, e.g., Example 8) is introduced into the bacterial host cell, cro can suppress  $P_R$  of the helper phage or lysogen *in trans*. Thus, recombinant lambdoid vectors comprising  $P_R$  are also preferably deficient in the Cro gene.

CII is responsible for inducing the expression of CI. CI also down regulates  $P_R$ . If a second vector (e.g., a helper phage or lysogen) comprising the CI gene that is CII inducible is introduced into the cell, expression of the CI protein from the second vector will be rapidly induced by the CII expressed from the lambdoid vector and interfere with the desired function of the  $P_R$  promoter. Thus, the operon comprising the lambda origin of replication is preferably also deficient in CII.

The  $P_R$  promoter directs transcription through (in order) *cro*,  $tR_1$ , *CII*, *O*, and *P*. The *O* gene comprises the origin of replication.  $tR_1$  terminates transcription from  $P_R$  before it gets to the origin of replication, unless the  
5 anti-terminator N protein acts at the *nutR* (N utilization site). Thus,  $tR_1$  could block or impair the function of the lambdoid origin of replication. Therefore, the operon preferably also lacks the  $tR_1$  transcription terminator or, alternatively, is used in conjunction with  
10 a helper virus that will express the N gene.

The *O* gene comprises the origin of replication. Therefore, if the *O* gene is deleted entirely, then a lambdoid origin of replication must be re-inserted into the operon. Alternatively, the production of the *O*  
15 protein can be prevented without deleting the *O* gene, e.g., by causing a frameshift mutations or the like. Additionally, transcription of the *Oop* RNA can be inhibited.

In another embodiment of the present invention, a  
20 promoter can be linked to a DNA comprising a lambdoid origin of replication, wherein the entire operon does not encode a protein. If the lambdoid origin of replication is from lambda, *O* and *P* proteins must be supplied in *trans* or inducibly from another locus of the vector,  
25 because the lambda origin of replication requires the presence of *O* and *P* to function.

The present invention also provides a gene transfer system. Any of the preceding lambdoid vectors can constitute a portion of the present inventive gene  
30 transfer system useful for (1) functional genomics (e.g., finding a function for an expressed sequence tag (EST) or identifying binding peptides from a library), (2) therapeutics (e.g., neovascularization or antisense RNA delivery), and (3) general research (e.g., site directed  
35 mutagenesis driven study of the structure-function relationships of a steroid receptor or other protein) and the like.



In addition to the present inventive lambdoid vectors, the present inventive system comprises a source of gene functions necessary to encapsidate lambdoid vectors and a source of gene functions necessary to complement the deficiency or conditional deficiency of the lambdoid origin of replication. These sources are preferably encoded by a nucleic acid, which is preferably DNA, but also can be RNA. Additionally, these sources can be encoded by one DNA or by multiple DNAs. For example, the deficient or conditionally deficient gene functions required for the operability of the lambdoid origin of replication can be provided *in trans* by the host bacterium (i.e., the bacterial genome or plasmids/episomes maintained within the host cell), a helper phage, or a lysogen, or *in cis* from a separate regulatable promoter located on the lambdoid vector. For ease of use, however, these gene functions are preferably provided by a phage or lysogen which also directs the encapsidation of the recombined lambdoid. Alternatively, encapsidation gene products (including at least the D gene product when a lambda packaging site is used and including at least the gene 10 protein when a T7 packaging site is used) can be provided by a helper virus or packaging extract (such as Gigapack™ packaging extracts, Stratagene). However, it should also be understood that lambdoid vectors can be used without encapsidation.

In one embodiment of the present inventive system, the source of the gene products allowing lambdoid replication and packaging of the lambdoid vector is in a non-competing helper lambdoid phage. To prevent competition with the lambdoid, the helper phage can be made replication and/or packaging deficient. For example, when the lambdoid vector comprises a phage origin of replication operably linked to the  $P_R$  promoter and is deficient in the gene encoding P and no other gene function essential for the replication of the phage, the

helper phage can supply P and the packaging components. If the helper phage is a lambda phage, then it preferably is a phage that produces clear plaques. Lambda phage of this phenotype are known in the art as lambda clear and are widely available. To reduce packaging efficiencies, the helper phage can lack a packaging site. This can be achieved, for example, by placing parallel lox sites around the packaging site(s). Therefore, if the system is employed in a bacterial cell expressing cre, the helper phage will undergo cre-lox mediated destruction of its packaging capability and will serve as a source of P and packaging proteins for the lambdid vector. The cre in this case can be supplied *in trans* (e.g., by a co-transfer of a plasmid or be supplied inducibly *in cis*).

Another embodiment of the present inventive system employs phage packaging components obtained from a defective lysogen. A defective lysogen can be made from a phage genome by introducing a modification into the genome and establishing lysogeny. The modification can, for example, reduce the lysogenic phage genome to less than about 73% of its wild-type size. This modification makes the lysogen defective in packaging because, in general, phage genomes must be between 73% and 110% of a wild-type phage size. Alternatively, the defective lysogen can be a lambda vector lacking a packaging site. Another alternative modification is to make one or more temperature-sensitive or suppressible amber mutations in an essential gene function of the helper phage. Preferably, the temperature-sensitive or suppressible amber mutation is not complemented by the lambdid vector. One way to prevent complementation is to use a lambdid vector having phage genetic elements obtained from a phage that has a different immunity than the helper phage.

A recombinant eukaryotic viral amplicon or genome obtained through double homologous recombination according to the present inventive method or system can

be isolated, purified, and transduced into a eukaryotic cell which is permissive for the growth of the (complete or replication-deficient) eukaryotic virus, irrespective of whether it has been encapsidated. This is  
5 advantageous for at least two reasons. The skilled artisan can know a priori that a correctly constructed eukaryotic genome has been transduced into a eukaryotic cell. Thus, if a recombinant virus does not propagate in that eukaryotic cell, the skilled artisan can be  
10 confident that the problem is not related to the lack of a proper recombination event. Additionally, large amounts of the eukaryotic viral genome can be quickly obtained prior to any use of a eukaryotic cell, thereby substantially accelerating the rate at which new  
15 eukaryotic viral stocks are obtained.

Encapsidation of the product vector and other vectors of the present invention facilitate certain uses of the vectors and storage of the vectors by protecting the DNA from the laboratory or clinical environment and  
20 can provide other advantages. Other advantages can be obtained by encapsidating the lambdid vector. For example, encapsidation can be used to linearize the lambdid vector (as disclosed above) resulting in a terminal eukaryotic viral ITR or LTR, which (as described  
25 above) is advantageous when the lambdid is transduced into a eukaryotic cell. Additionally, encapsidation allows the incorporation of a modified coat protein into the capsid to allow targeting of cells that are not normally transduced by the capsid (e.g., eukaryotic  
30 cells).

A modified coat protein, similar to those described in U.S. Patent 5,559,099 (Wickham et al.), and U.S. Patent Application 08/634,060 (Wickham et al.), U.S. Patent Application 08/700,846 (Wickham et al.), U.S.  
35 Patent Application 08/701,124 (Wickham et al.), and International Patent Application WO 97/20051, can redirect the targeting of the phage particle to a target

cell such as a cell located in, or obtained from, a eukaryotic organism (e.g., a human).

At the genetic level, the gene encoding the D protein (or another phage coat protein) can be modified by inserting DNA encoding a non-native amino acid sequence specific for a cell surface structure, a receptor (including cell surface liposaccharides and the like), an antibody, or an epitope. For the D protein, the insertion of the non-native sequence can be at the amino and/or carboxyl terminus (i.e., within about 10, preferably 3, amino acids of either terminus). Alternatively at the protein level, lambda D coat protein or other phage coat proteins can be chemically (i.e., covalently) or transiently (i.e., through biological interactions) modified by a bispecific molecule. Such a bispecific molecule has affinity for the lambdoid coat protein (whether modified or not), and (i) a cell surface structure, (ii) a receptor (including cell surface liposaccharides and the like), (iii) an antibody, or (iv) an epitope. The bispecific molecule can cross-link the vector with a target cell, thereby facilitating its uptake and expression.

One alternative to the lambda capsid comprising a chimeric D protein is the T7 capsid and a chimeric gene 10 protein. A chimeric gene 10 protein preferably has a non-native amino acid at its carboxyl terminus.

An encapsidated recombinant lambdoid vector that is targeted by a modified coat protein to a eukaryotic cell and comprises a eukaryotic genetic element has many uses including use as an *in vitro* or *in vivo* gene transfer vector. Of course, if the cell is a plant cell, the cell wall must first be permeablized, preferably by use of enzymes capable of digesting the cell wall. For example, a recombinant phage comprising such a chimeric coat protein having an RGD sequence (or a constrained RGD sequence), can be used to target the lambdoid or phage vector directly to a target cell having an  $\alpha v$  integrin.

The chimeric coat protein mediates binding to the surface of the eukaryotic cell and the encapsidated lambdid vector or recombinant phage genome is internalized in an endosome. Through the internalization process, the encapsidated DNA becomes substantially free of the capsid proteins that surround it, so that each genetic element capable of being expressed in a eukaryotic cell can be transcribed and (if appropriate) translated. The targeted vector is preferably internalized with an endosomolytic agent. Endosomolytic agents induce the rupture of endosomes and significantly increase the efficiency of expression of vectors taken up by endosomes. Chloroquine, calcium phosphate particles, adenoviral coat proteins (including adenoviral virions), and adeno-associated viral coat proteins (or virions) are illustrative of useful endosomolytic agents.

The lambdid vector can contain a site-directed recombination system such as flp-frt or cre-lox. Using the cre-lox system as an example, a gene capable of being expressed in a eukaryotic cell (e.g., a promoter operably linked to a VEGF<sub>121</sub> cDNA and an SV40 polyadenylation signal) can be placed adjacent to a eukaryotic episomal origin of replication (e.g., the EBV latent origin of replication, ori P), which together are flanked by parallel lox sites. When both the vector and endosomolytic agent complex are contacted to a cell that allows the function of the origin (e.g., a cell expressing the EBNA-1, which is required for operation of the EBV Ori P origin of replication as in Raji cells) and cre protein (the expression of cre also can be carried out in the phage genome under suitable conditions), they are internalized into an endosome and the vector is unencapsidated. The endosome is lysed by the endosomolytic agent allowing the unencapsidated vector to be acted upon by the cre protein. The cre protein acts on the site-directed recombination sites and effects the excision of a circular DNA comprising the genetic element

capable of being expressed and the EBV ori (i.e., an episome). In the case of the EBV Ori P, EBNA-1 expressed within the cell facilitates the long term maintenance of the episome. Of course, the episome expresses only the genetic elements it carries (e.g., VEGF<sub>121</sub>). The remainder of the lambdid vector eventually is lost from the cell, provided that it lacks a functional eukaryotic origin of replication. Thus, starting with a lambdid vector of the present invention, a eukaryotic cell can be (1) specifically targeted, (2) genetically modified to contain an episome, and (3) caused to express the protein encoded by the episome in the host. Significantly, gene transfer according to this method need not be accompanied by the expression of phage or viral gene products in the targeted eukaryotic cell. Therefore, the targeted cell is less vulnerable to an immune response and is minimally altered at the genetic level.

Optionally, an episomal vector (as described herein) can contain one or more DNA segments or genetic elements which are homologous to a eukaryotic host genome such that the expression cassette can be transferred into the host genome by homologous recombination. In that case, the elements that allow for integration of the expression cassette into the genome of the eukaryotic cell can obviate the requirement for an origin of replication that functions in a eukaryotic cell.

A lambdid vector also can be used to generate a replication-deficient eukaryotic virus in a suitable cell that does not complement for the replication deficiency of the eukaryotic virus and to support the replication of the vector. (A suitable eukaryotic cell for the production of a replication-deficient virus of a particular type is any cell that supports the production of a wild-type eukaryotic virus, and in this case does not complement the deficiency of the replication-deficient virus itself.)

In this embodiment, the lambdid vector comprises a genome of a eukaryotic virus comprising a deficiency in at least one (essential) gene function required for replication. The replication deficient viral genome

5 preferably also comprises a passenger gene of interest and two ITRs, one of which is preferably proximal (within about 250 bp, preferably within 100 bp, more preferably within 25 bp) to a phage packaging site. The replication-deficient eukaryotic viral genome is defined

10 to be between the ITRs on the DNA segment comprising the eukaryotic viral packaging site. To support the replication of the eukaryotic viral vector carried by the lambdid vector, the lambdid vector also comprises DNA sequences that are not between the ITRs and that provide

15 *in trans* the gene functions necessary for the replication of the viral vector that resides between the ITRs (and which is defined by the ITRs). The lambdid vector can be replicated in a bacterium and, if desired, encapsidated in a phage capsid comprising a chimeric coat protein (as

20 described above). The chimeric coat protein mediates internalization of the encapsidated lambdid into the eukaryotic cell. While in the eukaryotic cell, the sequences outside the ITRs complement the replication deficiencies of the deficient viral genome. The

25 eukaryotic viral vector produces its own coat and replication-deficient eukaryotic viral vectors are obtained. Significantly, this method can be designed such that there can be no homologous recombination event that would generate (contaminating) replication competent

30 eukaryotic virus by ensuring that no overlapping sequences between the replication deficient eukaryotic viral vector and the complementing genetic elements exist. In this way a stock of replication-deficient eukaryotic virus can be prepared without the need of

35 preparing a complementing cell line or using a helper virus. A lambdid vector illustrative of this embodiment is depicted in Figure 6.

The present invention also provides a system for the generation of recombinant DNA vectors. Any embodiment of the present inventive vector can constitute a portion of the present inventive system. The present inventive

5 system comprises at least a second DNA that comprises two DNA segments each of which have sufficient homology to the inventive vector to mediate homologous recombination and which flank or surround a DNA that is desirable to incorporate into the present inventive vector or into a

10 portion of the eukaryotic viral DNA or amplicon that forms a portion of the present inventive vector. In embodiments comprising a deficient or conditionally deficient lambdoid origin of replication, the present inventive system can comprise a third DNA that can

15 complement *in trans* the deficiency in a lambdoid origin of replication and, optionally, a fourth DNA that expresses a source of phage capsids that encapsidate intermediate or product vectors comprising the phage origin of replication. Either or both of the third and

20 fourth DNAs of the inventive system can be optionally incorporated into the genome of a bacterial cell and/or can be comprised by one DNA.

The skilled artisan will appreciate that each of the foregoing embodiments of the present inventive vector

25 enables certain embodiments of the present inventive method. The following descriptions will more fully illustrate the present inventive method.

According to the present invention, a DNA vector can be made and packaged by transfecting a bacterial cell

30 with any embodiment of the present inventive vector and a second vector that has two DNA segments that are sufficiently homologous to the first vector to enable a double homologous recombination event between the vectors. Preferably, both the first and second vectors

35 comprise at least one positive selection gene (which are preferably different), so that the cell can be grown under conditions that are selective for the maintenance



of both vectors in the cell. After maintaining the transfected bacterial cell for a suitable time in culture, or on a plate, a double homologous recombination event produces a vector that has a phage packaging site and that does not contain the regulatable anti-selective gene of the present invention.

Of course, other vector moieties will be present in that cell as well. These other vector moieties comprise the original or starting vectors and the derivative of vector 2 which comprises the anti-selective gene. The present invention allows the facile removal or elimination of these undesired vectors.

First, only the product vector and the original vector contain phage packaging sites. Vectors that do not contain the phage packaging site can be eliminated by causing the packaging of the present inventive vector and the product vector while within the bacterial cell and infecting the phage into a second population of cells.

Any suitable technique for encapsidating these vectors into a phage capsid can be used. For example, the bacterial cell may contain a lysogen which can be activated. Alternatively, the bacterial cell can be superinfected with a helper phage. The helper phage can be either a wild type phage or can be deficient in an important phage gene function, e.g., it can lack a functional origin or replication or a phage packaging site.

The encapsidated product vector can be isolated from the first vector by appropriate design of the first vector. For example, the first vector can be made too large or too small to be effectively encapsidated into the phage capsid. The type of phage capsid, of course, is determined by the type of phage packaging site found on the first vector (e.g., if the first vector comprises a cos site, then the capsid will be a lambdoid, preferably a lambda capsid).

Alternatively, the encapsidated vectors (i.e., the first vector and the product vector) can be infected or transfected into a population of cells under conditions such that the regulatable anti-selective gene becomes  
5 active. The method is then finished by allowing the cells to grow (since cells comprising the first vector will be at a strong selective disadvantage or may die), and harvesting the product vector from a primary colony or a culture of the cells. The skilled artisan will  
10 recognize that the growth period is selected to avoid the appearance of variants. The variants typically will not begin to substantially contaminate the culture or plate for at least about 24 hours after induction of the NSG. Of course, the method can also comprise a screening or  
15 sequencing step, if desired.

The skilled artisan will readily appreciate how to induce the anti-selective gene. For example, if the NSG is a constitutively expressed *sacB* gene, the NSG can be activated by supplying sucrose to the medium allowing  
20 leaven to be produced. A plethora of other embodiments are well known in the art. If an NSG is regulated by a small chemical inducer, e.g., *Tac-ccdB* gene, it can be activated by adding the inducer (e.g., IPTG) to the growth medium. If the anti-selective gene is the T7  
25 promoter linked to an NP-1 gene, this NSG can be activated simply by infecting a cell that expresses T7 RNA polymerase. Similarly, if the anti-selective gene is an SRG, e.g., the EM-7 promoter linked to a zeocin gene, the SRG can be activated simply by infecting a cell that  
30 expresses T7 RNA polymerase. Advantageously, when the EM-7 promoter is linked to a DNA encoding a positive selection protein, the SRG can serve two functions. In the first bacterial cell the constitutive promoter of the EM-7 gene will provide constitutive production of the  
35 positive selection protein. However, when the same gene is in a cell containing a suitable level of T7 RNA

polymerase, this otherwise positive selection gene becomes a strong anti-selective gene.

A preferred embodiment of the present invention which has been found to function as well as any other  
5 embodiment and better than a few embodiments comprises a first (inventive) vector that comprises a PSG that is either proximal or adjacent to an NSG and an independent positive selection gene. In this embodiment the PSG is a zeocin resistance gene and the independent positive  
10 selection gene is a kanamycin resistance gene, or yet more preferably, a tetracycline resistance gene. Additionally, in this embodiment of the present invention the inventive vector preferably comprises a pBR322 origin of replication.

15 In a further embodiment of the present invention, the first bacterial cell (into which the first and second vectors are transfected) is competent for homologous recombination, but the second population of cells into which the encapsidated products are infected (or  
20 transfected) is deficient in the ability to support homologous recombination. This phenotype can be obtained by a multiplicity of suitable mechanisms. One type of cell that is deficient in the ability to support homologous recombination is any cell deficient in recA.  
25 A multiplicity of recA deficient strains are publicly available.

Another embodiment of the present invention employs a first vector that comprises a lambdoid origin of replication. It is strongly preferred that the lambdoid  
30 origin of replication be defective or conditionally defective, and that the defect can be complemented in *trans* or otherwise mitigated by manipulation of the cellular environment. As in other embodiments of the present inventive method, the first and second vector are  
35 transfected into a bacterial cell. However, in the present embodiment, the double homologous recombination event is facilitated by infecting (or transfecting) the

cell with a defective or non-defective helper phage or by activating a defective or non-defective lysogen. The helper phage or lysogen complements the defective lambdoid origin *in trans*. As a result, the first vector  
5 begins lambdoid replication, which provides higher copy numbers of the first vector and substantially enhances the rate of homologous recombination. The helper function can be provided by lambda clear. The helper function can also be provided by a vector with a  
10 packaging site that can be disabled or deleted. For example, the packaging site of the helper can be flanked by site-directed homologous recombination sites (e.g., lox sites). Accordingly, if the first and second vector are initially transfected into a cell expressing a  
15 suitable recombinase (e.g., cre), when the helper phage is infected into the cell it will be not be capable of being packaged into capsids and cannot interfere with later steps of the inventive method. Even if the helper phage is encapsidated and carried to the next step of the  
20 inventive method, the helper vector can be eliminated by placing the second population of cells under conditions selective for the product vector and anti-selective for the helper phage. The skilled artisan will readily appreciate that additional permutations and combinations  
25 of the present invention can also be used.

#### Examples

The following examples further illustrate the present invention but should not be construed to be  
30 limiting in any way. Although the examples are illustrated with lambda vectors and adenovirus, the skilled artisan will appreciate that the following examples can be applied to other lambdoid vectors and to non-adenoviral eukaryotic viruses.

35

Example 1

The following example illustrates LOI<sup>Q</sup>VXB(Spe), a vector useful in the context of the present invention.

Referring to Figure 1, the LOI<sup>Q</sup>VXB(Spe) vector  
5 comprises a lambda operon P<sub>R</sub> that drives transcription through gene O. In this particular vector, Cro and CII comprise deletion mutations in essential regions of their coding sequences, thereby eliminating the Cro and CII  
10 gene functions. For example, Cro is deleted of amino acids 15-38 (i.e.,  $\alpha$  helices 2 and 3), and CII is deleted of amino acids 6-20. Protein O is still expressed.

The vector also comprises a Lac I<sup>Q</sup> operon. Downstream of the Lac I<sup>Q</sup> promoter and gene is a cos site. The orientation of the cos sites with respect to the P<sub>R</sub>  
15 promoter is the same as the orientation of the cos site with respect to P<sub>R</sub> found in wild-type lambda. Each of the aforementioned genetic elements are contained on one DNA segment comprising a Pac I site at each terminus. The vector further comprises a kanamycin resistance gene and  
20 the p15 origin of replication from pACYC177 (New England BioLabs).

A first transgene expression cassette (e.g., a CMV promoter operably linked to DNA encoding the bacterial Lac Z gene, or alternatively human VEGF<sub>121</sub>cDNA, and an  
25 SV40 polyadenylation sequence) is adjacent to the Ad5 position 1-355 segment. Continuing from the transgene expression cassette is a DNA segment comprising Ad5 sequences from positions 27,082 to 32,852 which have sequences from 27,860 to 30,805 deleted and which are  
30 obtained from Xba I digestion of Ad5. The Spe I site in this vector is unique. The E. coli  $\beta$ -glucuronidase gene and SV40 early polyadenylation signal are placed next to the Ad5 sequence terminating at position 32,852 and in the same orientation as the aforementioned transgene. A  
35 DNA segment corresponding to Ad5 from position 35,565 to position 35,935 resides next to the  $\beta$ -glucuronidase

coding sequence. This places the  $\beta$ -glucuronidase gene under control of the Ad5 E4 promoter.

#### Example 2

5 This example illustrates useful modifications of LOI<sup>Q</sup>VXB(Spe).

LOI<sup>Q</sup>VXB(SpeCC) shown in Figure 2 is made by a deletion spanning the coding sequences from the Cro gene through the CII gene of LOI<sup>Q</sup>ZXB(Spe). A deletion to the O  
10 gene of LOI<sup>Q</sup>ZXB(Spe) produces LI<sup>Q</sup>ZXB(Spe) shown in Figure 3. A deficiency in the O gene can be made by cutting it with Bgl II and re-ligating the O gene which results in the loss of a small essential fragment of the O gene without disrupting the lambdoid origin of  
15 replication. The deletion of Cro through CII is approximately lambda coordinates 38,041 to 38,653. This also removes tr<sub>1</sub>.

#### Example 3

20 This example demonstrates the production of lambdid vectors comprising all of an adenoviral genome except for portions of the E1, E3, and E4 regions.

An Ad5 virus containing an Spe I site at position 3,328 of the wild-type genome was generated by standard  
25 virus construction techniques. Digestion with Spe I yielded an expected fragment of about 23.7 kbp which was isolated. The isolated fragment was inserted into LOI<sup>Q</sup>VXB(Spe) to generate the lambdid vector LGV<sub>11</sub>VXB which is shown in Figure 4. By an analogous process, each of  
30 the vectors of Examples 1-3 and the like can be used to generate a lambdid vector containing an adenovirus.

The lambdid vector can be amplified and digested with Pac I, and the Pac I segment containing the adenoviral sequences can be transferred to a eukaryotic  
35 cell capable of supporting the growth of the recombinant adenovirus. In the present example, 293/ORF6 cells (see International Patent Application WO 95/34671, Kovesdi et

al.) would be suitable cells, because they complement the deficiencies in the essential gene functions deleted from the E1 and E4 regions of the adenoviral genome. The adenoviral stock produced in this manner is free of replication competent adenovirus and wild-type adenovirus since none of these are packaged into the lambdoid phage.

Alternatively, a bacterial cell comprising LGV<sub>11</sub>VXB can be infected with a helper phage (or a lysogen it contains can be activated). The presence of helper phage functions results in the linearization of LGV<sub>11</sub>VXB at the cos site and the encapsidation of the linearized vector. As can be seen by inspection, linearization results at the cos site generates an ITR near one terminus of the DNA. Therefore, the encapsidated, linearized vector can be transduced into a permissive eukaryotic cell (e.g., 293/ORF6 cells), which in turn is followed by unencapsidation of the vector, and propagation of the eukaryotic viral gene transfer vector (i.e., the adenoviral vector).

20

#### Example 4

The construction of an adenovirus by using viral arms is a time consuming process. If multiple regions of the genome need to be altered, either sequential virus construction processes are employed or partially complementary arms from different recombinant viruses are required. Often suitable restriction sites are not readily available. Further, a negative selection pressure can exist with respect to the desired adenovirus in a eukaryotic cell, which can further hinder attempts to obtain the desired vector. This example demonstrates a suitable solution to a long felt need and demonstrates the increased rate and ease of generation of various adenoviral vectors that can result from the use of the present inventive lambdoid vectors and system.

35

As disclosed above, replacement of a desired region of a lambdoid vector is facilitated by positive and/or

negative selection. Preferably, both positive and negative selection are used together for optimum ease of vector construction. Figure 5 depicts a process wherein two homologous recombination steps are used to generate a  
5 final lambdid vector.

First, a cassette is introduced into the region to be modified by homologous recombination. The cassette contains a positive and negative selection gene and preferably introduces a unique restriction site. The  
10 negative selection gene is placed under the control of a regulatable promoter or can be placed under the control of a constitutive promoter when the negative selection gene product catalyzes the conversion of a non-toxic substance (which can be provided or withheld) into a  
15 lethal metabolite. The intermediate lambdid vector thereby produced is called Lambdid select (L-sel). L-sel contains genes for both tetracycline and zeocin resistance whereas neither precursor vector confers resistance to both antibiotics to a bacterium containing  
20 only one of the vectors.

A third vector, comprising sequences to be introduced into the L-sel vector and homologous to L-sel at two distinct loci which flank the negative selection ("death") gene, is transduced into a bacterial cell  
25 comprising L-sel. L-sel and the third vector recombine. The recombination event excises the negative selection gene from L-sel at the same time that the desired sequence is introduced. The reaction gives rise to a population of vectors in which the desired product is under-represented. Therefore, the desired (final)  
30 lambdid vector ("lambdid desired") is enriched by activation (e.g., provision of a substrate) or induction of the negative selection gene. Bacteria comprising undesired reactants and products do not propagate. The  
35 desired product is, therefore, easily identified with routine screening.



Ampicillin, kanamycin, zeocin, and geneticin (G418) are illustrative of positive selection antibiotics useful in the context of this example. A Tac (Trp and Lac hybrid) promoter which is repressible by Lac I operably  
5 linked to a DNA encoding OmpA FLAG/NP-1 fusion protein is illustrative of a negative selection gene useful in the context of this example. OmpA FLAG/NP-1 is a rat defensin lacking its cognate signal sequence. The Tac promoter is inducible by IPTG.

10 The unique restriction site introduced into L-sel by the selection cassette is useful (but optional) in at least two respects. Linearized DNA with free ends have increased rates of homologous recombination. Combining  
15 linearized L-sel with the target DNA will yield higher rates of recombination. The unique restriction site is also of use when the recombination event occurs (this event dimerizes the vectors) between intact circular DNAs when a single, rather than multiple, recombination event occurs. In that case, the recombinant vectors can be  
20 digested with the unique restriction enzyme. Advantageously, the unique restriction enzyme can be expressed from an inducible gene *in vivo*, which provides continuous cutting of the moieties comprising the unique restriction enzyme site and prevents the need to isolate  
25 the DNA for restriction digestion. All of the non-recombinant and singly recombined vectors will be linearized. The linearized DNAs are selected against when transferred into bacteria since they do not stably transform bacteria. The non L-sel vector can be selected  
30 against by antibiotic selection. In contrast, the dimerized vector can undergo a second round of homologous recombination to generated the desired product. The vector population can be purified from the bacteria, digested at the unique restriction site, and re-  
35 transduced into a bacteria to enrich the vector population for the desired product. The requirement for restriction can be avoided with the negative selection

cassette in L-sel vectors, by inducing the expression of the "death" gene in all non recombined L-sel vectors.

#### Example 5

5        This example demonstrates the generation of adenovirus from a lambdid vector.

      The lambdid vector LGV<sub>11</sub>VXB (Figure 4) is amplified in a bacterial host and isolated. The vector is digested with Pac I, which produces a DNA segment that contains at  
10    least one fragment that is highly homologous to an adenoviral sequence. The DNA fragment comprising the DNA segment highly homologous to an adenoviral sequence is transferred into a eukaryotic cell culture permissive for the growth of that adenovirus (e.g., 293/ORF6 cells).  
15    After multiple passages, cytopathic effect is observed.

#### Example 6

      This example demonstrates the production of recombinant D protein comprising a sequence that targets  
20    the protein or a phage capsid comprising the protein to the surface of a eukaryotic cell, thereby effecting its uptake into endosomes of the eukaryotic cell.

      A plasmid comprising the DNA encoding the D gene operably linked to the Tac promoter, pD100, is prepared  
25    by conventional techniques. Standard site directed mutagenesis is used to introduce a DNA encoding either the amino acid sequence (a)Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Ala Cys Asp Cys Arg Gly Asp Cys Phe Cys Gly [SEQ ID NO:2] or  
30    (b) Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Lys Lys Lys Lys Lys Lys Lys [SEQ ID NO:3] into the coding sequence of D. The added amino acid sequence is placed at the carboxy terminus of the D protein but also can be placed at the amino terminus of the D protein. By including the  
35    sequence of SEQ ID NO:2, the D protein will specifically bind to any cell that expresses the  $\alpha v \beta 3$  integrin on its surface. By including the sequence of SEQ ID NO:3, the D

protein will bind to a cell having heparin sulfate on the surface.

The recombinant D protein is overexpressed in bacteria and isolated by conventional means. During the  
5 isolation of the recombinant D protein, the bacterial culture is separated by differential centrifugation to separate inclusion bodies, if any, from soluble material. The extent of soluble D protein will depend on the particular placement of the added amino acid sequence.  
10 At least 20% of the protein partitions to the supernatant, thus demonstrating proper folding of the D protein. The affinity of the D protein for eukaryotic cells can be confirmed using any suitable assay, including direct binding measurements and inhibition  
15 assays.

#### Example 7

This example illustrates the use of a modified T7 vector for gene transfer to eukaryotic cells.

20 The expression cassette CMV-GFP is positioned immediately 3' of gene 10 in the genome of T7 so that it is transcribed leftward (with respect to the linear T7 genome). The expression cassette CMV-GFP consists essentially of the CMV immediate early promoter, a coding  
25 sequence for the Green Fluorescence Protein (Gibco BRL Life Technologies), and the SV40 early polyadenylation signal. The T7 gene 10 promoter region is deleted from the phage genome, resulting in very low levels of its expression. However, a modified gene 10 product (i.e.,  
30 modified p10) is provided by a plasmid in trans. Its expression is regulated by the gene 10 promoter so that it is overexpressed. Amino acid 344, the last amino acid of p10A, is changed to valine, and the stop codon is changed to glutamic acid before addition of a constrained  
35 RGD sequence. The 3' terminal coding sequence and carboxyl terminal amino acid sequence of the modified gene 10 product are, e.g., GTG GAA GAG ATC TAT AGC GGT

Val Glu Glu Ile Tyr Ser Gly

AGC GGC AGC GGT AGC GCG TGC GAT TGT CGT GGT GAT TGC TTC  
Ser Gly Ser Gly Ser Ala Cys Asp Cys Arg Gly Asp Cys Phe

5

TGC GGC [SEQ ID NO:4]

Cys Gly [SEQ ID NO:5]

When this recombinant T7 phage is contacted to  
10 eukaryotic cells comprising the  $\alpha$ v integrin and treated  
with chloroquine, GFP activity can be detected in the  
cells 24-48 hours later.

#### Example 8

15 This example illustrates a straightforward method of  
using a lambdid vector to generate a product-vector, such  
as a recombinant eukaryotic viral vector, suitable for  
use in gene transfer to eukaryotic cells. The  
product-vectors generated by the present method comprise  
20 a eukaryotic viral amplicon. This example teaches and  
illustrates a general method. However, the example also  
includes a specific embodiment to aid understanding of  
this method.

This method utilizes a lambdid vector, Vector 7, and  
25 another DNA, Vector 8. One embodiment of Vector 7 is  
depicted in Figure 7. One embodiment of Vector 8 is  
depicted in Figure 8.

#### Vector 7

30 Vector 7 comprises a eukaryotic viral amplicon, a  
eukaryotic viral vector, or sequences highly homologous  
to a eukaryotic viral vector (i.e., a eukaryotic viral  
DNA). Because this method preferably generates  
product-vectors comprising at least the genetic elements  
35 that are necessary and sufficient to form a eukaryotic  
viral amplicon, the eukaryotic viral DNA carried by  
Vector 7 also preferably comprises the elements required

to make an amplicon. However, one or more elements of an amplicon can be transferred to Vector 7 by homologous recombination with Vector 8 or another suitable DNA. The particular embodiment of Vector 7 depicted in Figure 7 carries an adenoviral vector, which is deficient in the E1 and E4 regions of the adenoviral genome. Figure 7 also depicts two terminal ITRs and an adenoviral packaging site, because these three genetic elements are necessary and sufficient to form an adenoviral amplicon.

Vector 7 can (and usually does) comprise additional sequences of a eukaryotic viral vector. The particular embodiment of Vector 7 illustrated in Figure 7 comprises a complete wild-type adenovirus with the exception that most of the E1 region (Ad5 coordinates 356 to 3,327) and the E4 region (Ad5 coordinates 32,832 to 35,564) are replaced by heterologous genetic elements.

The purpose of Vector 7 (in this example) is to facilitate homologous recombination into one region of the eukaryotic viral DNA that it carries. In the particular embodiment illustrated here, the E1 region of the adenoviral vector comprises either a highly-regulatable negative selection gene (NSG), or a dual selection cassette (DSC), which is inserted into, or in place of, a region of the eukaryotic viral DNA. The substitution of the NSG, or DSC (which by definition comprises an NSG), for the E1 region in Figure 7 dictates that the E1 region or a region comprising the E1 region will be replaced by homologous recombination with Vector 8 in this method. It is preferred (but not essential) that Vector 7 comprises a DSC, rather than a NSG. After homologous recombination, the NSG will be activated to select against bacteria comprising the NSG.

In the initial steps of the procedure, the bacteria transduced with Vectors 7 and 8 are grown under conditions that select for bacteria harboring either Vector 7, or Vectors 7 and 8. Vector 7 has an independent positive selection gene (kanamycin resistance

in the present embodiment) and selective pressure for Vector 7 can be obtained by adding kanamycin to the growth medium. However, selective pressure for Vector 7 also can be obtained by utilizing the positive selection gene of the DSC (zeocin resistance in the illustrated embodiment). Selection for the PSG of the DSC is advantageous because the PSG and the NSG resident in the DSC are (in terms of genetics) more tightly linked because of their physical proximity to each other than are the NSG and the independent positive selection gene. To obtain the highest degree of efficiency in obtaining the desired vectors in the present method, so-called "background" propagation of undesired vectors is preferably limited to the greatest extent possible. Therefore, the use of the positive selection gene of the DSC to maintain pressure for Vector 7 is preferred to the use of the independent positive selection gene in the initial stages of this method. The skilled artisan will, of course, recognize that the growth medium could be formulated to be selective for both positive selection genes of Vector 7 (e.g., in the illustrated embodiment, formulated to contain both zeocin and kanamycin).

The eukaryotic viral vector carried by Vector 7 can have other modifications in addition to the insertion of a DSC or negative selection gene into or in place of a region of the eukaryotic viral vector. The illustrated embodiment of the present method teaches this by showing that the E4 region of the adenoviral vector is replaced by a Transcriptionally Inert Spacer (TIS). However, it will be appreciated that many other modifications can be made to the eukaryotic viral vector. The depicted TIS is an SV40 polyadenylation sequence, followed by a bacterial  $\beta$ -glucuronidase coding sequence, followed by a human  $\beta$ -globin polyadenylation sequence. The TIS element is incorporated to improve the characteristics of the adenoviral vector produced in the present example. TIS

elements are more thoroughly described in International Patent Application WO 97/21826.

An important feature of Vector 7 is that it contains two DNA segments (homology regions) that are highly homologous to two DNA segments (homology regions) of Vector 8. These homology regions of Vectors 7 and 8 are used to mediate homologous recombination between the two vectors. In the particular embodiment illustrated herein, the adenoviral sequences from coordinate 1 to 355 and from coordinate 3328 to at least about 5,678 are present in both Vector 7 and Vector 8 and are depicted in each figure as striped and stippled boxes to indicate their identity.

Vector 7 also has a packaging site providing for encapsidation into a lambdoid capsid (e.g., a lambda cos site). The lambdoid encapsidation site is preferably proximal to an ITR of the eukaryotic viral DNA so that that the ITR will become proximal to a (free) terminus of the DNA following the linearization of the lambdoid vector that occurs during encapsidation into a lambdoid capsid.

The Vector 7 depicted in Figure 7 also comprises a  $LacI^Q$  gene, a low copy number, bacterial origin of replication, and an independent positive selection gene.

The  $LacI^Q$  gene of the Vector 7 depicted in Figure 7 is optional. In the depicted embodiment, it allows for the tight regulation of the Tac promoter that governs the depicted NSG (in this case the NSG forms part of the DSC). The  $LacI^Q$  gene overexpresses the lac repressor, which effectively silences the Tac promoter in the absence of galactose or a galactose analog (e.g., IPTG). If a promoter other than the Tac promoter is used to drive the expression of the NSG, if a  $LacI^Q$  strain is used, or if other highly effective means of controlling the negative selection pressure of the NSG are employed, then the  $LacI^Q$  gene can be deleted from Vector 7 without effect.

The low copy number origin of replication serves to stably maintain Vector 7 in the bacterial cell when the lambdoid origin is inoperable. The vector depicted in Figure 7 comprises more than 38 kbp. Accordingly, it is advantageous to incorporate a low copy number origin of replication, such as the p15 Ori (as shown in Figure 7) or as the pBR322 ori (not shown). While not wishing to be bound to any particular theory, it is believed that low copy number origins of replication help to maintain the integrity of large, autonomously-replicating DNAs, such as large lambdoid vectors.

The independent positive selection gene does not reside within the dual selection cassette, nor within any region of the lambdoid vector intended to participate in the homologous recombination reaction with Vector 8. Therefore, the independent positive selection gene of Vector 7 will become part of the desired product-vector, Vector 9 (Figure 9).

Following homologous recombination between Vectors 7 and 8, the vectors depicted in Figures 9 and 10A-B will be produced. The vector of Figure 9 comprises the desired adenoviral vector, but will not comprise the positive selection gene of the dual selection cassette (which resides within the adenoviral vector sequences in Figure 7). In order to select for bacterial cells comprising the vector depicted in Figure 9, the cells are grown in or on medium selective for cells comprising the independent positive selection gene (derived from Vector 7). The independent positive selection gene shown in Figure 7 is a kanamycin gene. In contrast, the medium is not selective for the PSG of the DSC since this selection gene now resides only on undesired products. Accordingly, all transformed bacterial cells in this particular example are grown in the presence of kanamycin, but not zeocin at this point in the procedure.

Vector 7 also comprises a lambda origin of replication. The lambda origin of replication comprises



at least two gene functions: a site to assemble the replication proteins and a promoter that drives transcription through these sequences. The lambda origin depicted comprises the  $P_R$  operon which has been rendered  
5 deficient in at least O or P. This is advantageous, inter alia, to prevent run-away replication of Vector 7.

#### Vector 8

The vector depicted in Figure 8 comprises two non-  
10 adjacent segments that are highly homologous to sequences in the adenoviral vector comprised by Vector 7. Between these two non-adjacent sequences is an expression cassette comprising a DNA encoding a protein of interest, and, operably linked thereto, a promoter that functions  
15 in at least some eukaryotic cells (e.g., a target cell of the adenoviral vector comprised by Vector 7 or Vector 9). In the depicted embodiment, Vector 8 comprises an EF-1 $\alpha$  promoter (Uetsiki et al., J. Biol. Chem., 264, 5791-5798 (1989)) operably linked to a VEGF<sub>121</sub> coding sequence,  
20 forming a synthetic VEGF<sub>121</sub> gene. The VEGF<sub>121</sub> gene is flanked by regions having high homology to adenoviral sequences in the embodiment of Vector 7 depicted in Figure 7.

Vector 8 also comprises an optional positive  
25 selection gene (e.g., an ampicillin resistance gene), which is preferably a different gene than the positive selection gene of the dual selection cassette and the independent positive selection gene of Vector 7. Vector 8 preferably does not comprise a phage packaging site  
30 that is compatible with the phage packaging site of Vector 7. That is, in the event that Vector 8 comprises a phage packaging site, that phage packaging site will be selected such that it does not direct the encapsidation of Vector 8 into a capsid capable of encapsidating  
35 Vector 7. Alternatively, Vector 8 can be designed to be too large or too small for efficient encapsidation or can have another suitable impediment to encapsidation.

Optionally, Vector 8 can additionally comprise a lambdoid origin of replication.

The vectors of Figures 7 and 8 (i.e., Vectors 7 and 8) having been transformed into a single bacterial host can homologously recombine (through a double crossover) to generate the vectors depicted in Figures 9 and 10A-B. The vector depicted in Figure 9 is the desired product. Both vectors depicted in Figures 7 and 8 are closed circular DNAs. This fact decreases the efficiency of homologous recombination, which is a phenomenon that occurs at a low frequency, even under optimum conditions. Additionally, the vector depicted in Figure 9 will be found in a minority of bacterial cells growing in a culture. Other cells growing in the same culture will contain one of more of the vectors depicted in Figures 7, 8, and 10A-B. The culture of bacterial cells also will comprise a vector produced by a single crossover event between the vectors of Figures 7 and 8. The product of a single crossover by homologous recombination (a vector dimer or supervector) will comprise all the nucleotides of the vectors of both Figures 7 and 8. If a second homologous recombination event could be encouraged, this supervector would give rise to either the vectors of Figures 7 and 8, or to the vectors of Figure 9 and 10A-B. These impediments are suitably overcome by infection of the population of transduced cells (comprising Vectors 7, 8, 9, and Vectors 10A-B) with a helper phage (e.g., lambda clear) or by activating a (helper) lysogen within the cell.

The helper phage or lysogen is preferably conditionally defective such that its presence allows for the lambdoid replication and encapsidation of the lambdoid vector, but does not itself become packaged. Such a helper phage or lysogen can be obtained by elimination of the packaging site or other suitable mechanism as is discussed elsewhere. If a defective helper phage or defective helper lysogen is employed, then the

propagation of the helper can be prevented and separation of the helper phage and Vector 9 is easily achieved.

Example 9 is directed to conditionally defective helper phage and lysogens. However, to more clearly illustrate

- 5 the present invention the remainder of the present example assumes that the helper phage or lysogen is not defective.

10 *Super-transduction by Helper Phage or Activation of a Lysogen*

- The helper phage or activated lysogen, when present in a bacterial cell comprising the vectors depicted in Figures 7 and 8, causes the lambda origin resident on Vector 7 to mediate lambdoid replication. Lambdoid  
15 replication is well-known to enhance the rate of homologous recombination.

- Additionally, the helper phage or activated lysogen provides all the gene functions necessary to replicate itself (unless a defective phage or lysogen is used) and  
20 any lambdoid vectors contained in the same cell. As a consequence, vectors of appropriate size (i.e., a size between about 73% and about 110% of the wild-type phage genome) that comprise a phage packaging site (e.g., a lambda cos site) are packaged into phage capsids.

- 25 The vector depicted in Figure 8, and vectors derived from the backbone of Vector 8, lack a compatible phage packaging site (i.e., in the present example, a cos site). The vectors of Figures 7 and 9, however, do comprise a suitable packaging site and lambda origin of  
30 replication. They are also designed to be roughly the same size as the wild-type helper phage (i.e., between 73% and 110% of the lambda genome). Thus, the helper phage directs the encapsidation of the vectors of Figures 7 and 9 into (lambda) capsids. Any supervectors within  
35 the cell also may be packaged providing that they are not larger than the upper size limit (of about 110% of a wild-type genome) for packaging into a capsid.

The present method continues by obtaining a phage-like lysate (i.e., a lysate of encapsidated lambdoid vectors and possibly helper phage) and infecting a culture of suitable bacteria with the lysate. These infected cells will primarily comprise (1) helper phage, (2) Vector 7, and (3) Vector 9. The infected bacteria are grown under conditions that (1) are selective for the desired product-vector ("Vector 9") and (2) activate the negative selection gene (i.e., conditions that are anti-selective for Vector 7 and undesired product-vectors). Since the helper phage lacks the independent PSG (e.g., the Kan resistance gene), it is anti-selected. Moreover, the cell is preferably lysogenic, which prevents propagation of the helper phage or lysogen. The desired product-vector, which is Vector 9, is therefore efficiently separated from those products that are not efficiently encapsidated.

These bacteria comprising a mixed population of reactant and product vectors are clonally isolated, sub-cultured, screened to ascertain their identity, and propagated to provide a recombinant lambdoid vector comprising a desired eukaryotic viral vector (pDesired).

The pDesired vector can then be utilized as recited in a variety of ways. For example, the pDesired vector is prepared for transduction into a eukaryotic cell. Preparation for transduction into a eukaryotic cell can comprise packaging (e.g., by means of a helper phage) into a phage capsid. Alternatively, preparation for induction into a eukaryotic cell can comprise linearization near an ITR of the eukaryotic viral vector (but not within the viral vector). The recombinant lambdoid, having been prepared for transduction into a eukaryotic cell, is then transduced into a eukaryotic cell that is permissive for the replication of the eukaryotic viral vector. The eukaryotic cell is cultured and the eukaryotic viral vector is obtained by a modified Hirt procedure or any other suitable procedures.

Example 9

This example illustrates how to make and use a defective helper phage or defective helper lysogen in the context of Example 8.

In Example 8, a phage-like lysate comprising Vectors 7, 8, 9, 10A and 10B and the helper phage/lysogen is obtained and transfected into a population of bacteria in which the helper phage will not grow. The inability of the helper phage/lysogen to grow on this population of bacteria can be a result of either the helper phage/lysogen or of the cell it is transfected into. In Example 8, the second strain of bacteria is a lysogen having the same immunity as the helper. Thus, infection by the helper in Example 8 does lyse the cells and the helper does not grow. The present example is directed to other methods of preventing the growth of the helper.

For example, the helper can be conditionally deficient. An example of this embodiment is when the first bacterial cell (i.e., the bacterial cell used for recombination of Vectors 7 and 8) can provide gene O and the helper can be deficient in gene O function. Thus, when the second bacterial population is infected with the phage-like lysate, the conditional deficiency in the helper in gene O will not be complemented and the helper will not grow.

Alternatively, the second bacterial population can overexpress cro. Cro will then bind to the helper genome and give rise to lysogeny, rather than lytic growth of the helper.

Yet another alternative is for the helper phage to contain a temperature sensitivity that is not complemented or mitigated in the second bacterial cell population.

It will therefore be appreciated that any suitable method to prevent the helper phage or lysogen that is present in the phage-like lysate from propagating and

entering the lytic cycle in the second population of cells can be used to separate Vector 9 from the helper phage or lysogen.

#### Example 10

5 This example illustrates an embodiment of the present inventive method wherein a first vector and a second vector undergo homologous recombination to form a product vector. The first vector employed in this example contains a DSC and does not contain a lambdoid  
10 origin of replication.

Figure 13 depicts p15E1(Z), which is a second vector of the present invention. This plasmid comprises the p15 ori and a kanamycin resistance gene obtained from pACYC177. The bla gene from pACYC177 was replaced with  
15 Ad5 sequences 1 to 5,788. Adenoviral sequences 356 to 3327 were replaced with an expression cassette comprising the CMV promoter operably linked to the Lac Z gene and an SV40 polyadenylation signal. p15E1(Z) was co-transfected with pAdE1(BN)E310BR, which is depicted in Figure 14 (and  
20 is a pSelect of the present invention). The Sty I site of pBR322 was changed to Pac I. The Lac I<sup>o</sup> expression cassette and a cos site were inserted into the Pac I site. Adenoviral sequences 1 to 35,935 in which sequences 356 to 4122 are replaced with a DSC and  
25 sequences 28,592 to 30,470 (Xba I to Xba I) are deleted were placed adjacent to the cos site. The DSC (of this example) has the following sequence, SEQ ID NO:6

```
TCAGTCCTGC TCCTCGGCCA CGAAGTGCAC GCAGTTGCCG GCCGGGTCGC GCAGGGCGAA 60
30 CTCCCGCCCC CACGGCTGCT CGCCGATCTC GGTCATGGCC GGCCCGGAGG CGTCCCGGAA 120
GTTCTGTGGAC ACGACCTCCG ACCACTCGGC GTACAGCTCG TCCAGGCCGC GCACCCACAC 180
CCAGGCCAGG GTGTTGTCCG GCACCACCTG GTCCTGGACC GCGTGATGAA CAGGGTCACG 240
35 TCGTCCCGGA CCACACCCCC GAAGTCGTCC TCCACGAAGT CCCGGGAGAA CCCGAGCCGG 300
TCGGTCCAGA ACTCGACCGC TCCGGCGACG TCGCGCGCGG TGAGCACCGG AACGGCACTG 360
40 GTCAACTTGG CCATGACGGC GCCCCATTCT CCATTTCAGG TGCGCAACTG TTGGGAAGGG 420
CGATCGGTGC GGGCCTCTTC GCTATTACGC CAGCTGGCGA AAGGGGGATG TGCTGCAAGG 480
CGATTAAGTT GGGTAACGCC AGGGTTTTCC CAGTCACGGA CGTTGTAAAA CGACGGCCAG 540
45 TGAATTTTGC ATGCATGCAA AATCCGTAAT CATGGCCATG GTGGCCCTCC TATAGTGAGT 600
```

CGTATTATAC TATGCCGATA TACTATGCCG ATGATTAATT GTCAACACGT GCTGCAGCCC 660  
 5 GGGGGATCCC GCGAAATTAA TACGACTCAC TATAGGGAGA CCACAACGGT TTCCCTCTAG 720  
 AAATAATTTT GTTAACTTT AAGAAGGAGA TATACATATG AAAAAGACAG CTATCGCGAT 780  
 TGCAGTGGCA CTGGCTGGTT TCGCTACCGT TGCGCAAGCT GACTACAAGG ACGACGATGA 840  
 10 CAAGCTGGCA TTAAATGCC GATCCATGGT AACCTGCTAC TGTCGTCGTA CTCGTTGCGG 900  
 TTTCCGTGAA CGTCTGTCCG GTGCTTGCGG TTACCGTGGT CGTATCTACC GTCTGTGCTG 960  
 TCGTTAA 967  
 15

This sequence (SEQ ID NO:6) contains:

<u>SEQ ID NO:6</u>	<u>Gene Fragment</u>	<u>Notes</u>
1-375	sch-ble (zeocin resistance)	
385-543	Lac Z fragment	seqs. 16-174
562-579	Lac Z fragment	seqs. 1-18 (fourth base is changed to "G")
580-657	EM-7 promoter	
672-760	T7 gene 10 promoter	
758-820	OmpA signal sequence	
821-844	Flag epitope	
866-967	Rat Defensin NP-1	

**Table 1.** Coordinates of the DSC given in Example 10.

In the vector depicted in Figure 14, the EM-7 promoter of  
 20 the DSC is oriented toward the left ITR. The right ITR  
 is next to the Pac I site that is closest to the  
 tetracycline resistance gene.

Figure 15 depicts pAdE1(Z)E3(10)BR, which is a pDesired vector of the present invention.

25 pAdE1(Z)E3(10)BR is isogenic with pAdE1(BN)E310BR except  
 that the Lac Z expression cassette of p15E1(Z) and  
 adenoviral sequences 3328 to 4122 have replaced the DSC.

pAdE1(BN)E3(10)BR was transformed into DH5 $\alpha$  cells  
 and selected on ampicillin. From a saturated culture 100  
 30 microliters, 1 microliter, or 10 nanoliters was plated  
 onto both tetracycline containing medium and tetracycline  
 plus IPTG containing medium. The number of surviving  
 colonies is reflected in Table 2 below:

**Tabl 2.** Susceptibility of DH5 $\alpha$  cells to the anti-selective effects of the DSC.

<u>Volume of Culture</u>	<u>Number of Colonies Formed on Tet</u>	<u>Number of Colonies Formed on Tet + IPTG</u>
100 $\mu$ l	lawn	13
1 $\mu$ l	full plate	0
10 nl	500	0

5

There were about 5 million cells in 100  $\mu$ l of saturated culture. Accordingly, the selective pressure provided by the DSC is sufficient to allow less than 1 in about  $10^5$  cells comprising the activated DSC to grow.

10

#### Example 11

This example illustrates an embodiment of the present inventive method wherein a first vector and a second vector undergo homologous recombination to form a product vector. The first vector employed in this example contains a DSC and does not contain a lambdoid origin of replication.

Figure 16 depicts pAdE1(Z)E3/4(B)IQCos, which is a first vector (or pSelect) of the present invention comprising an SRG. This vector comprises a serotype 5 adenoviral genome modified by (i) replacing coordinates 356 to 2,787 with an expression cassette comprising the CMV promoter operably linked to the Lac Z gene and an SV40 polyadenylation sequence, and (ii) replacing coordinates 27,084 to 35,564 with an SRG. The SRG comprises an EM-7 promoter functionally linked to the Lac Z-sch ble gene. The SRG is transcribed toward the right ITR of the adenoviral genome. This vector also comprises a p15 origin of replication, a kanamycin resistance gene, and a Laq I<sup>Q</sup> gene located proximally to the cos site. The



Lac I<sup>0</sup> gene is transcribed toward the cos site. The cos site is adjacent to the adenoviral left ITR.

The vector pAdE1(Z)E3/4(B)IQCos was transformed into a population of BL21(DE3) cells in the presence of  
5 kanamycin. The BL21(DE3) cell line is the well known cell line that was made and described in 1986 by Studier and Moffatt. BL21(DE3) cells were made by lysogenising an E. coli with lambda 21 phage carrying T7 RNA polymerase under the LacUV5 promoter. Consequently, BL21(DE3) cells  
10 overexpress T7 RNA polymerase when exposed to IPTG. Various volumes of a saturated culture of the transformed BL21(DE3) cells were plated on a 10 cm agarose plate comprising suitable quantities of kanamycin and IPTG. After maintaining the cells at 37°C for 16 hours, 100  
15 microliters of culture gave rise to 50 colonies, however, 1 microliter of culture gave rise to only 3 secondary or pin point colonies, and 10 nanoliters of culture resulted in no colonies. In contrast, when plated on kanamycin only, 100 microliters of culture resulted in a lawn, 1  
20 microliter resulted in distinct colonies lacking substantial space between colonies (i.e., the plate was overloaded or full of colonies), and 10 nanoliters of culture resulted in about 200 colonies. These results demonstrate that less than about 1 in 10<sup>4</sup> bacteria  
25 comprising the SRG of pAdE1(Z)E3/4(B)IQCos are able to survive or effectively grow in the presence of T7 RNA polymerase.

#### Example 12

30 This example illustrates that the present inventive method provides an efficient and straightforward method of making a recombinant DNA vector via homologous recombination.

The bacterial strain LE392 was co-transformed with  
35 pAdE1(BN)E3(10)BR and p15E1(Z) and maintained under selective pressure for ampicillin and kanamycin. Using standard techniques, a phage lysate was made from the

transformed LE392 culture with lambda clear. A portion of the lysate (100  $\mu$ l) was used to infect the cells of 1 ml of an saturated culture of a DH5 $\alpha$ /lambda lysogen. Serial dilutions of the infected lysogen culture were plated under selective pressure for kanamycin, or ampicillin, tetracycline and IPTG. Table 3 shows the number of colonies obtained under each condition.

**Table 3.** Number of colonies observed

Volume of Culture Plated	Number of Colonies Observed on Kanamycin	Number of Colonies Observed on
		Ampicillin, Tetracycline, and IPTG
1000 nl	1530	170
10 nl	300	1

10

These results demonstrate that between about 0.1% and 0.4% of the single homologous recombination events were resolved by a second homologous recombination event to produce the desired product vector. This result was confirmed by re-plating the colonies. Of the re-plated colonies 94% were found to be sensitive to kanamycin and resistant to ampicillin. Seventeen of eighteen colonies had the expected pattern of DNA fragmentation when isolated DNA was restriction digested with Hind III and Pac I. These results demonstrate that the present inventive vectors and methods enable the production of a recombinant DNA vector using homologous recombination (single and double) to generate product vectors with an efficiency of at least about 5%, and preferably with an efficiency of at least about 80%.

15

20

25

All of the references cited herein, including patents, patent applications, and publications, are hereby incorporated in their entireties by reference.

30

While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments may be used and that it is intended 5 that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the following claims.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- 5 (i) APPLICANT:  
(A) NAME: GENVEC, INC.  
(B) STREET: 12111 PARKLAWN DRIVE  
(C) CITY: ROCKVILLE  
(D) STATE: MD  
10 (E) COUNTRY: US  
(F) POSTAL CODE (ZIP): 20852  
(G) TELEPHONE: (301)816-0396  
(H) TELEFAX: (301)816-0085
- 15 (A) NAME: MCVEY, DUNCAN  
(B) STREET: 6016 MUNCASTER MILL ROAD  
(C) CITY: DERWOOD  
(D) STATE: MD  
(E) COUNTRY: US  
20 (F) POSTAL CODE (ZIP): 20855
- (A) NAME: KOVESDI, IMRE  
(B) STREET: 7713 WARBLER LANE  
(C) CITY: ROCKVILLE  
25 (D) STATE: MD  
(E) COUNTRY: US  
(F) POSTAL CODE (ZIP): 20855
- (A) NAME: BROUGH, DOUGLAS  
(B) STREET: 3900 SHALLOWBROOK LANE  
(C) CITY: OLNEY  
(D) STATE: MD  
30 (E) COUNTRY: US  
(F) POSTAL CODE (ZIP): 20832
- 35 (A) NAME: ZUBER, MOHAMMED  
(B) STREET: 4993 ROBIN COURT  
(C) CITY: FREDERICK  
(D) STATE: MD  
40 (E) COUNTRY: US  
(F) POSTAL CODE (ZIP): 21703
- 45 (ii) TITLE OF INVENTION: PHAGE VECTORS AND METHODS OF USE
- (iii) NUMBER OF SEQUENCES: 5
- (iv) COMPUTER READABLE FORM:  
50 (A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
- 55 (vi) PRIOR APPLICATION DATA:  
(A) APPLICATION NUMBER: US 60/072,222  
(B) FILING DATE: 22-JAN-1998
- (vi) PRIOR APPLICATION DATA:  
60 (A) APPLICATION NUMBER: US 60/049,072  
(B) FILING DATE: 09-JUN-1997
- (2) INFORMATION FOR SEQ ID NO: 1:
- 65 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 467 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

TACGCGCATT GCAAATGAGT TGCTGGAAGC TGTGATGCTG GCCGGATTAA CACAGCACCA 60  
GCTTCTGGTC TTCCTGGCTG TCATGCGCAA AACATATGGC TTTAATAAAA AACTGGATTG 120  
10 GGTGAGCAAC GAGCAACTTT CCGAGTTGAC CGGGATATTG CCGCACAAGT GTTCTGCTGC 180  
AAAAAGCGTT CTGGTAAAGC GTGGGATTCT TATTCAGAGC GGGCGGAATA TCGGCATTAA 240  
15 TAATGTGGTC AGTGAATGGT CAACATTACC CGAATCAGGT AAGAAAAATA AAGTTTACCT 300  
GAAAGAGGTA AATTTACCTG AATCAGGTAA AAAAAGTTTA CCCAAATCAG GTAAAGGCGT 360  
TTACCCGAAT CAGGTAAACA CAAAAGACAA ACTAACAAAA GACAATATAA AACCTTTTTTC 420  
20 GTCCGAGAAT TCTGGCGAAT CCTCTGACCA ACCAGAAAAC GATCTTC 467

(2) INFORMATION FOR SEQ ID NO: 2:

25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: unknown  
(D) TOPOLOGY: unknown

30 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

35 Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Ala Cys Asp Cys Arg Gly  
1 5 10  
Asp Cys Phe Cys Gly  
20

40 (2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 17 amino acids  
45 (B) TYPE: amino acid  
(C) STRANDEDNESS: unknown  
(D) TOPOLOGY: unknown

50 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

55 Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Lys Lys Lys Lys Lys Lys  
1 5 10 15  
Lys

(2) INFORMATION FOR SEQ ID NO: 4:

60 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 69 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: unknown  
65 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GTGGAAGAGA TCTATAGCGG TAGCGGCAGC GGTAGCGCGT GCGATTGTCG TGGTGATTGC 60  
 5 TTCTGCGGC 69

## (2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 23 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: unknown  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Val Glu Glu Ile Tyr Ser Gly Ser Gly Ser Gly Ser Ala Cys Asp Cys  
 1 5 10 15  
 Arg Gly Asp Cys Phe Cys Gly  
 20

## (2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 967 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: unknown  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

TCAGTCCTGC TCCTCGGCCA CGAAGTGCAC GCAGTTGCCG GCCGGGTCGC GCAGGGCGAA 60  
 CTCCCGCCCC CACGGCTGCT CGCCGATCTC GGTCATGGCC GGCCCGGAGG CGTCCCGGAA 120  
 40 GTTCGTGGAC ACGACCTCCG ACCACTCGGC GTACAGCTCG TCCAGGCCGC GCACCCACAC 180  
 CCAGGCCAGG GTGTTGTCCG GCACCACCTG GTCCTGGACC GCGTGATGAA CAGGGTCACG 240  
 45 TCGTCCCGGA CCACACCCCC GAAGTCGTCC TCCACGAAGT CCCGGGAGAA CCCGAGCCGG 300  
 TCGGTCCAGA ACTCGACCGC TCCGGCGACG TCGCGCGCGG TGAGCACCAG AACGGCACTG 360  
 GTCAACTTGG CCATGACGGC GCCCCATTTC CCATTGAGG TGCGCAACTG TTGGGAAGGG 420  
 50 CGATCGGTGC GGGCCTCTTC GCTATTACGC CAGCTGGCGA AAGGGGGATG TGCTGCAAGG 480  
 CGATTAAGTT GGGTAACGCC AGGGTTTTTC CAGTCACGGA CGTTGTAAAA CGACGGCCAG 540  
 55 TGAATTTTGC ATGCATGCAA AATCCGTAAT CATGGCCATG GTGGCCCTCC TATAGTGAGT 600  
 CGTATTATAC TATGCCGATA TACTATGCCG ATGATTAATT GTCAACACGT GCTGCAGCCC 660  
 GGGGGATCCC GCGAAATTAA TACGACTCAC TATAGGGAGA CCACAACGGT TTCCCTCTAG 720  
 60 AAATAATTTT GTTTAACTTT AAGAAGGAGA TATACATATG AAAAAGACAG CTATCGCGAT 780  
 TGCAGTGGCA CTGGCTGGTT TCGCTACCGT TGCGCAAGCT GACTACAAGG ACGACGATGA 840  
 65 CAAGCTGGCA TTAAATGCC GATCCATGGT AACCTGCTAC TGTCGTCGTA CTCGTTGCGG 900  
 TTTCCGTGAA CGTCTGTCCG GTGCTTGCGG TTACCGTGGT CGTATCTACC GTCTGTGCTG 960

WO 98/56937

PCT/US98/12158

68

TCGTTAA

967

5

## WHAT IS CLAIMED IS:

1. A DNA vector comprising a portion of a eukaryotic viral genome comprising an ITR, a regulatable negative selection gene, and a phage packaging site.

2. The DNA vector of claim 1, further comprising a second ITR, such that the vector comprises at least a eukaryotic viral amplicon lacking a packaging site.

3. The DNA vector of claim 1 or 2, comprising a eukaryotic viral packaging site.

4. The DNA vector of claim 2 or 3, wherein said first ITR and said second ITR flank said negative selection gene such that said vector comprises a portion of a eukaryotic viral genome comprising a negative selection gene.

5. The DNA of any of claims 1-4, wherein said vector is circular.

6. The DNA of any of claims 1-5, further comprising a positive selection gene that is proximal to said negative selection gene in order to form a dual selection cassette.

7. The DNA vector of any of claims 1-6, further comprising an independent positive selection gene, wherein said independent positive selection gene is not embedded within said portion of a eukaryotic viral genome.

8. The DNA vector of any of claims 1-5 comprising an independent positive selection gene or a positive selection gene.



9. The DNA vector of any of claims 4-6, comprising an independent positive selection gene, wherein said independent positive selection gene is not on the portion of the vector beginning at the first ITR, extending  
5 through the negative selection gene, and ending at the second ITR.

10. The DNA vector of any of claims 7-9, wherein said independent positive selection gene is selected from  
10 the group of antibiotic resistance genes consisting of kanamycin ( $\text{kan}^r$ ), ampicillin ( $\text{amp}^r$ ), tetracycline ( $\text{tet}^r$ ), and zeocin ( $\text{zeo}^r$ ).

11. The DNA vector of claim 10, wherein said  
15 antibiotic gene is selected from the group consisting of tetracycline and zeocin.

12. The vector of claim 11, wherein tetracycline is  
20 the positive selection gene of the dual selection cassette.

13. The DNA vector of any of claims 1-12, wherein said negative selection gene is selected from the group consisting of NP-1, *sacB*, *ccdB*, *tet*, *parD*, and *Kid*,  
25 fusion proteins of the same, and variants of the same.

14. A DNA vector comprising a portion of a eukaryotic viral genome comprising an ITR, a stringent promoter operably linked to an open reading frame  
30 comprising a strong bacterial signal for the initiation of translation, and a phage packaging site.

15. The vector of claim 14, wherein said stringent promoter is a T7 promoter.  
35

16. The vector of claim 15, wherein said T7 promoter is contained within an EM7 promoter.

17. The DNA vector of any of claims 14-16, further comprising a second ITR, such that the vector comprises at least a eukaryotic viral amplicon lacking a packaging site.

18. The DNA vector of any of claims 14-17, comprising a eukaryotic viral packaging site.

19. The DNA vector of claim 17 or 18, wherein said first ITR and said second ITR flank said stringent promoter such that said vector comprises a portion of a eukaryotic viral genome comprising a stringent promoter operably linked to an open reading frame comprising a strong bacterial signal for the initiation of translation.

20. The DNA of any of claims 14-19, wherein said vector is circular.

21. The DNA of any of claims 14-20, further comprising a positive selection gene that is proximal to said stringent promoter operably linked to an open reading frame comprising a strong bacterial signal for the initiation of translation in order to form a dual discrimination cassette.

22. The DNA vector of any of claims 14-21, further comprising an independent positive selection gene, wherein said independent positive selection gene is not embedded within said portion of a eukaryotic viral genome.

23. The DNA vector of claim 22, wherein said independent positive selection gene is selected from the group of antibiotic resistance genes consisting of kanamycin, ampicillin (amp<sup>r</sup>), tetracycline (tet<sup>r</sup>), and zeocin (zeo<sup>r</sup>).

24. The DNA vector of claim 23, wherein said antibiotic gene is selected from the group consisting of tetracycline and zeocin.

10

25. The vector of claim 24, wherein zeocin is the positive selection gene of the dual discrimination cassette.

26. The DNA vector of any of claims 14-20, further comprising a negative selection gene that is proximal to said stringent promoter operably linked to an open reading frame comprising a strong bacterial signal for the initiation of translation in order to form a dual discrimination cassette.

27. The DNA vector of any of claims 1-26, wherein said vector comprises a deficient or conditionally deficient lambdoid origin of replication.

25

28. The DNA vector of claim 27, wherein said lambdoid origin of replication is a lambda origin of replication and wherein said vector is deficient or conditionally deficient in one or both of the O gene and the P gene.

30

29. The DNA vector of claim 27 or 28, wherein said lambdoid origin of replication is obtained from a lambdoid phage having an immunity that is the same as a lambdoid phage selected from the group consisting of lambda, 21,  $\phi$ 80,  $\phi$ 81, 82, 424, and 434.

35

30. The DNA vector of claim 27 or 28, wherein said lambdoid origin of replication is obtained from a lambdoid phage selected from the group consisting of 21,  $\phi$ 80,  $\phi$ 81, 82, 424, and 434.

5

31. The DNA vector of any of claims 27-30, wherein said DNA segment comprising a lambdoid origin has a sequence selected from the group consisting of (i) 37,951-37,591 with a deletion of 38,041-38,653 of lambda, (ii) 38,663-39,591 of lambda, (iii) 39,004-39,200 of  
10 lambda, (iv) 39,004-39,173, (v) a modified lambda sequence 38,663-39,591, wherein sequences 39,095-39,118 are replaced by a "G" and the A residue at position 39,076 is deleted, (vi) a modified lambda sequence  
15 39,004-39,200, wherein sequences 39,095-39,118 are replaced by a "G" and the A residue at position 39,076 is deleted, (vii) a modified lambda sequence 39,004-39,173, wherein sequences 39,095-39,118 are replaced by a "G" and the A residue at position 39,076 is deleted, (viii) Phi80  
20 sequence (Genbank Accession Symbol BP80ER) 3,253-5,159 deleted of 3,355-4,148 (ix) phi80 sequence 4,188-5,159, (x) phi80 sequence 4,567-4,764, (xi) phi80 sequence 4,567-4,727, (xii) SEQ ID NO:1 (is from Phi82), (xiii) coordinates 235-467 of SEQ ID NO:1, and (xiv) coordinates  
25 235-432 of SEQ ID NO:1.

32. The DNA vector of any of claims 27-30, wherein said lambdoid origin of replication is obtained from a segment of a lambdoid phage comprising one or more  
30 replicative gene functions required for the operability of said origin of replication, wherein said vector is conditionally deficient in at least one of said replicative gene functions, and wherein said conditional deficiency is caused at least in part by a regulated  
35 promoter or is caused at least in part by a temperature-sensitive mutation within said conditionally deficient replicative gene.

33. The DNA vector of any of claims 27-30, wherein said lambdoid origin of replication is obtained from a segment of a lambdoid phage comprising one or more  
5 replicative gene functions required for the operability of said origin of replication, wherein said vector is conditionally deficient in at least one of said replicative gene functions, and wherein said conditional deficiency is caused at least in part by a deletion of a  
10 portion of said replicative gene.

34. The DNA vector of any of claims 1-33, wherein said phage packaging site is proximal to said ITR of said eukaryotic viral amplicon.  
15

35. The vector of any of claims 1-34, comprising an origin of replication that functions in a bacterial cell.

36. The DNA vector of any of claims 1-35, wherein  
20 said portion of a eukaryotic viral genome is a portion of an adenoviral genome.

37. The DNA vector of any of claims 1-36, wherein the phage packaging site is a cos site.  
25

38. A system comprising the DNA vector of any of claims 1-37, a second DNA that comprises two DNA segments that mediate a double homologous recombination event with said vector of any of claims 1-37, and a DNA that  
30 expresses a source of phage capsids that encapsidate vectors comprising said phage packaging site of said DNA vector of claim 1-37.

39. A system comprising the DNA vector of any of claims 27-37, a second DNA that comprises two DNA segments that mediate a double homologous recombination event with said vector of any of claims 27-37, a third  
5 DNA that expresses said at least one deficient or conditionally deficient gene of said lambdoid origin, and a fourth DNA that expresses a source of phage capsids that encapsidate vectors comprising said lambdoid origin of replication of said DNA vector of claim 27-37.

10

40. The system of claim 39, wherein either or both of said third DNA and said fourth DNA are incorporated into the genome of a bacterial cell.

15

41. The system of claim 39 or 40, wherein said system comprises a fifth DNA, wherein said fifth DNA comprises said third DNA and said fourth DNA.

42. The system of claim 41, wherein said fifth DNA  
20 is comprised by a lysogen, a defective lysogen, a defective phage, or a non-defective phage.

43. A method of making and packaging a DNA vector comprising  
25 transfecting a bacterial cell with a first vector and a second vector, wherein said first vector comprises a eukaryotic viral ITR, a phage packaging site, and a regulatable anti-selective gene flanked by a first DNA segment and a second DNA segment that have sufficient  
30 homology to said second vector to mediate a double homologous recombination event with said second vector, maintaining said bacterial cell under conditions to allow double homologous recombination to occur and produce a product vector comprising said phage packaging  
35 site that does not contain said regulatable anti-selective gene, and

placing the vector under *in vivo* conditions such that the product vector is encapsidated in a phage capsid.

5           44. A method of isolating the DNA vector produced according to claim 43 comprising infecting the encapsidated product vector into a population of cells under conditions such that said regulatable anti-selective gene is active, allowing the cells to grow, and  
10           harvesting said DNA vector from a lysate of said second cell.

          45. A method of making a recombinant DNA comprising  
          (i) transfecting a bacterial cell with a first  
15       vector and a second vector, wherein said first vector comprises a phage packaging site, and a regulatable anti-selective gene flanked by a first DNA segment and a second DNA segment that have sufficient homology to said second vector to mediate a double homologous  
20       recombination event, wherein said regulatable anti-selective gene is flanked by a first eukaryotic viral ITR and a second eukaryotic viral ITR, and wherein said first DNA segment and said second DNA segment can be said first eukaryotic viral ITR and said second viral ITR or can be  
25       different,

          (ii) maintaining said bacterial cell under conditions to allow double homologous recombination to occur and produce a product vector comprising said phage packaging site that does not contain said regulatable  
30       anti-selective gene,

          (iii) placing the vector under *in vivo* conditions such that the product vector is encapsidated in a phage capsid and obtaining a lysate comprising encapsidated product vectors,

(iv) infecting said lysate into a second bacterial population and placing the population under conditions sufficient to activate the regulatable anti-selective gene such that cells comprising said regulatable anti-selective gene are substantially prevented from growing,

5 (v) placing said second population of cells under conditions sufficient to provide for the propagation of said second cell and the replication of said product vector, and

10 (vi) isolating said product vector to obtain a substantially pure product vector.

46. The method of claim 45, wherein said first vector comprises a positive selection gene that is proximal to said regulatable anti-selective gene thereby forming a dual selection cassette, wherein said second vector comprises a positive selection gene that is not encoded by said first vector, and wherein in step (ii) the cell is placed under conditions selective for the first vector.

47. The method of claim 46, wherein said first vector further comprises a independent positive selection gene, and wherein in step (v) the population of cells is placed under conditions selective for said independent positive selection gene.

48. The method of claim 47, wherein the positive selection gene of the dual selection cassette consists of a tetracycline resistance gene and said independent positive selection gene consists of a zeocin resistance gene.

49. The method of any of claims 43-48, wherein the cells of said population of cells are deficient in at least one gene required for host-directed homologous recombination.



50. The method of claim 49, wherein said population of cells are deficient in recA.

- 5           51. A method of making a DNA comprising
- (i) transfecting a bacterial cell with a first  
vector and a second vector, wherein said first vector  
comprises a phage packaging site, a stringently regulated  
gene comprising stringent promoter operably linked to an  
10 open reading frame comprising a strong bacterial signal  
for the initiation of translation, said stringently  
regulated gene being flanked by a first DNA segment and a  
second DNA segment that have sufficient homology to said  
second vector to mediate a double homologous  
15 recombination event with said second vector; wherein said  
stringently regulated gene is embedded in a portion of a  
eukaryotic viral genome, and wherein said portion of a  
eukaryotic viral genome optionally comprises said first  
DNA segment and/or said second DNA segment,
- 20           (ii) maintaining said bacterial cell under  
conditions to allow homologous recombination to occur and  
produce a product vector comprising said phage packaging  
site that does not contain said stringently regulated  
gene, and
- 25           (iii) placing the vector under *in vivo* conditions  
such that the product vector is encapsidated in a phage  
capsid and obtaining a lysate comprising encapsidated  
product vectors,
- (iv) infecting said lysate into a second bacterial  
30 population, plating said second population onto a solid  
growth medium to facilitate the production of at least  
one primary colony, and placing the population under  
conditions sufficient to activate said stringent promoter  
such that cells comprising said stringent promoter are  
35 substantially growth retarded and do not form primary  
colonies,
- (v) selecting a primary colony, and

(vi) isolating said product vector from said primary colony to obtain a substantially pure product vector.

5           52.     The method of claim 51, wherein said first vector comprises a positive selection gene that is proximal to said stringently regulated gene thereby forming a dual discrimination cassette, wherein said second vector comprises a positive selection gene that is  
10     not encoded by said first vector, and wherein in step (ii) the cell is placed under conditions selective for the first vector.

15           53.     The method of claim 52, wherein said first vector further comprises an independent positive selection gene, and wherein in step (v) the population of cells is placed under conditions selective for said independent positive selection gene.

20           54.     The method of claim 53, wherein the stringently regulated gene of the dual selection cassette consists of a zeocin resistance gene and said independent positive selection gene consists of a tetracycline or kanamycin resistance gene.

25           55.     The method of any of claims 51-54, wherein the cells of said population of cells are deficient in at least one gene that is required for bacterial cell-directed homologous recombination.

30           56.     The method of claim 55, wherein said population of cells are deficient in recA.

57. A method of making a DNA comprising a recombinant eukaryotic viral amplicon, said method comprising (a) transducing a bacterial cell with the DNA of any of claims 27-37 and a second DNA having a DNA  
5 segment with high homology to a DNA segment of said first vector, and (b) transducing said bacterial cell with a defective phage or a non-defective phage, or activating a defective or non-defective lysogen within said cell, such that said lambdoid origin of replication is operable and  
10 said DNA of any of claims 27-37 and said second DNA undergo a double homologous recombination event to form a desired DNA.

58. The method of claim 57, wherein said lysogen,  
15 defective lysogen, defective phage, or non-defective phage is lambda clear.

59. The method of claim 57, wherein said lysogen, defective lysogen, defective phage, or non-defective  
20 phage has a genome and a phage packaging site, wherein said phage packaging site of said lysogen, defective lysogen, defective phage, or non-defective phage is missing or can be rendered non-functional without isolating said genome of said lysogen, defective lysogen,  
25 defective phage, or non-defective phage.

60. The method of claim 59, wherein said phage packaging sequence is flanked by parallel site-directed homologous recombination sites and wherein said bacterial  
30 cell expresses a site-directed homologous recombinase.

61. The method of claim 60, wherein said site-directed homologous recombination sites are lox sites and said site-directed homologous recombinase is cre.  
35

62. A method of generating a eukaryotic gene transfer vector, said method comprising:

(i) transducing a bacterial cell with (i) the DNA vector of any of claims 27-37 and (ii) a second DNA comprising at least one DNA segment having high homology to said first vector,

5 (ii) supplying (i) a source of gene products that complement the deficiency or conditional deficiency in said lambdoid origin of replication and (ii) phage capsid components sufficient to encapsidate a DNA vector comprising said phage packaging site of said vector of  
10 claim 27-37,

(iii) obtaining a population of encapsidated vectors,

(iv) transducing said population of encapsidated vectors into a population of bacteria,

15 (v) growing said population of bacteria transduced by said population of vectors under selective conditions sufficient to select for bacteria harboring said independent positive selection gene and to select against bacteria harboring said negative selection gene or said  
20 stringently regulated gene, and

(vi) culturing a single bacterium that propagates under said selective conditions of step (e) in order to obtain a culture of a bacterium comprising a DNA vector comprising a eukaryotic gene transfer vector.

25

63. The method of claim 62, wherein said source of gene products that complement the deficiency or conditional deficiency in said lambdoid origin of replication and phage capsid components sufficient to  
30 encapsidate a DNA vector comprising said phage packaging site is a lambdoid phage.

64. The method of claim 63, wherein said lambdoid phage is lambda.

35

65. The method of claim 64, wherein said lambdoid phage is lambda clear.

66. A method of making a desired vector comprising a desired eukaryotic viral amplicon, said method comprising:

- 5       (i) transforming a first population of bacterial cells with a first vector having a phage packaging site, a conditionally inoperative lambdoid origin of replication, an independent positive selection gene, and a eukaryotic viral DNA with an anti-selective gene embedded in said eukaryotic viral DNA, and a second DNA  
10       having two DNA sequences with high homology to said first vector flanking a DNA sequence of interest to be inserted into said viral amplicon, under conditions that are permissive of homologous recombination,
- 15       (ii) expressing in said cell a source of phage gene functions sufficient to provide for the operation of said conditionally deficient origin of replication and sufficient to encapsidate vectors comprising a suitable  
20       length of DNA and said phage packaging site, such that wherein said source is an activated lysogen or a superinfected phage, to obtain a mixed population of encapsidated vectors, said mixed population comprising a desired lambdoid vector that comprises a desired  
25       eukaryotic viral amplicon,
- 25       (iii) obtaining a phage-like lysate of said mixed population of encapsidated vectors,  
          (iv) transducing a second population of bacterial cells with said phage-like lysate,  
          (v) maintaining said transduced second population of  
30       bacteria under conditions selective for said first independent positive selection gene and anti-selective for said superinfected phage and bacteria comprising said negative selection gene or stringently regulated gene,  
          to isolate a colony comprising said desired lambdoid  
35       vector comprising said desired eukaryotic viral amplicon.

67. A library comprising a multiplicity of recombinant DNA vectors of any of claims 1-37, said multiplicity of recombinant DNA vectors comprising eukaryotic genetic elements that may be the same or
- 5 different and are obtained from a population of DNA comprising a multiplicity of genetic elements.




FIG. 1




FIG. 2






FIG. 3





FIG. 4

**FIG. 5**








FIG. 6



**FIG. 10A**





FIG. 10B

**FIG. 11**







FIG. 12



**FIG. 13**




FIG. 14




FIG. 15




FIG. 16




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/86, 7/01</b>	<b>A3</b>	(11) International Publication Number: <b>WO 98/56937</b> (43) International Publication Date: 17 December 1998 (17.12.98)
<p>(21) International Application Number: PCT/US98/12158</p> <p>(22) International Filing Date: 9 June 1998 (09.06.98)</p> <p>(30) Priority Data: 60/049,072 9 June 1997 (09.06.97) US 60/072,222 22 January 1998 (22.01.98) US</p> <p>(71) Applicant (for all designated States except US): GENVEC, INC. [US/US]; 12111 Parklawn Drive, Rockville, MD 20852 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): McVEY, Duncan, L. [US/US]; 6016 Muncaster Mill Road, Derwood, MD 20855 (US). BROUGH, Douglas, E. [US/US]; 3900 Shallowbrook Lane, Olney, MD 20832 (US). ZUBER, Mohammed [US/US]; 4993 Robin Court, Frederick, MD 21703 (US). KOVESDI, Imre [CA/US]; 7713 Warbler Lane, Rockville, MD 20855 (US).</p> <p>(74) Agents: KILYK, John, Jr. et al.; Leydig, Voit &amp; Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report.</p> <p>(88) Date of publication of the international search report: 11 March 1999 (11.03.99)</p>	

(54) Title: CHIMERIC VECTORS COMPRISING A PHAGE PACKAGING SITE AND A PORTION DERIVED FROM THE GENOME OF A EUKARYOTIC VIRUS

## (57) Abstract

The present invention provides an improved method of making eukaryotic gene transfer vectors comprising homologous recombining lambdoid vectors with a second DNA in a bacterium to generate recombinant eukaryotic viral gene transfer vectors as well as lambdoid vector used in the inventive method and an inventive system comprising the lambdoid vector.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

Int l Application No  
PCT/US 98/12158

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 C12N15/86 C12N7/01		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 21007 A (VIAGENE INC) 11 July 1996	1,5-12, 27-31, 33-37,67
Y	see the whole document, especially page 7, lines 17-26 and page 8, lines 1-3	2-4, 38-48, 57-66
Y	--- WO 96 25506 A (RHONE POULENC RORER SA ;CROUZET JOEL (FR); NAUDIN LAURENT (FR); OR) 22 August 1996  see the whole document	2-4, 38-48, 57-59, 62-66
Y	--- WO 97 09439 A (GENVEC INC ;MCVEY DUNCAN L (US); KOVESDI IMRE (US)) 13 March 1997 see the whole document --- -/--	60,61
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "8" document member of the same patent family		
Date of the actual completion of the international search  18 November 1998		Date of mailing of the international search report  02/12/1998
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Mandl, B



## INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 98/12158

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GHOSH-CHOUDHURY G. ET AL.: "HUMAN ADENOVIRUS CLONING VECTORS BASED ON INFECTIOUS BACTERIAL PLASMIDS" GENE, vol. 50, no. 1/03, 1 January 1986, pages 161-171, XP002004335 see the whole document, especially page 170, left column, last 4 lines and right column, lines 1-3 see the whole document ----	1-13, 34-38, 43-48, 57-67
Y	HARDY S. ET AL.: "CONSTRUCTION OF ADENOVIRUS VECTORS THROUGH CRE-LOX RECOMBINATION" JOURNAL OF VIROLOGY, vol. 71, no. 3, March 1997, pages 1842-1849, XP000670223 see the whole document ----	1-13, 34-38, 43-48, 57-67
A	EGGLESTON A. K. AND WEST S. C.: "Exchanging partners: recombination in E. coli." TRENDS IN GENETICS, vol. 12, no. 1, 1996, pages 20-25, XP002081567 see the whole document ----	49,50, 55,56
A	GROSS G. AND HAUSER H.: "Heterologous expression as a tool for gene identification and analysis." JOURNAL OF BIOTECHNOLOGY, vol. 41, 1995, pages 91-110, XP002084909 see page 94, left-hand column, paragraph 2 - right-hand column, paragraph 1; figure 2 -----	14,21,26

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 98/12158

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9621007 A	11-07-1996	US 5736388 A AU 4610396 A	07-04-1998 24-07-1996
WO 9625506 A	22-08-1996	FR 2730504 A AU 4723596 A BR 9607583 A CA 2210956 A CZ 9702554 A EP 0809704 A FI 973309 A HU 9800260 A NO 973663 A SK 110097 A	14-08-1996 04-09-1996 07-07-1998 22-08-1996 12-11-1997 03-12-1997 12-08-1997 28-05-1998 08-08-1997 03-06-1998
WO 9709439 A	13-03-1997	US 5801030 A AU 6912296 A CZ 9800612 A EP 0850312 A NO 980838 A PL 325372 A	01-09-1998 27-03-1997 15-07-1998 01-07-1998 21-04-1998 20-07-1998